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Treatment of Head and Neck Squamous Cell Carcinoma, HNSCC, often requires 
multimodal therapy, including radiation therapy. The efficacy of radiotherapy in controlling 
locoregional recurrence, the most frequent cause of death from HNSCC, is critically 
important for patient survival.  One potential biomarker to determine radioresistance is TP53, 
whose alterations are predictive of poor radiation response. The following work shows that 
the p53 transcriptional target, p21, is crucial in initiating and maintaining senescence in 
HNSCC, through its ability to regulate reactive oxygen species (ROS). With the use of a 
novel system to evaluate the impact of the TP53 missense mutations, we were able to 
distinguish that cells with a partially functional TP53, that are resistant to radiation induced 
senescence, were able to senescence under persistent exposure to low levels of the ROS, 
hydrogen peroxide, or with a transient overexpression of p21 in combination with radiation.  
Each of these treatments created long term elevation of ROS, which was not seen in radiation 
only treatment.  This data demonstrates that the level of ROS is crucial in overcoming 
inhibition of radiation induced senescence when initiating a partially functional p53’s 
transcription of p21. In turn, p21’s ability to sustain elevated levels of ROS is necessary to 
allow for a long-term oxidative stress, ensuring an active p53-p21-ROS signaling loop with 
an end result of senescence. 
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We continued our work by investigating the mechanism by which mutp53 HNSCC 
cells were exhibiting their radioresistance. Noticing that mutp53 cells had a significantly 
higher baseline level of ROS, when compared to wtp53 cells, we were able to determine that 
these cells were able to sustain and thrive in a high ROS environment due to their ability to 
regulate proteins affiliated with elevated antioxidant levels. Observing that long term 
elevated p21 in combination with radiation or persistent exposure to elevated ROS alone 
were able to induce a significant level of senescence in partially functional TP53 HNSCC 
cells, we applied therapeutic approaches to mimic each condition, achieving promising 
results. This work emphasizes the importance of considering TP53 status when selecting a 
patient’s treatment options. Overall, our data offer a rationale to consider the use of either 
ROS inducing agents or therapies that increase p21 expression in combination with radiation 
as approaches in HNSCC cancer therapy.   
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Chapter 1: Introduction 
 
1.1  Head and Neck Squamous Cell Carcinoma 
       1.1.1. Incidence Statistics and Anatomy of Head and Neck Squamous   
                Cell Carcinoma 
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of 
cancer worldwide, with an average of 600,000 new cases diagnosed and 300,000 deaths 
estimated each year (1). In the United States, 50,000 new cases of HNSCC, with an estimated 
8,000 deaths occurred in 2010 (2). Also, with a ratio of 2:1 vs. 4:1, men are significantly 
affected more than women. Head and neck cancers originate in the squamous cells lining the 
mucosal surfaces of the head and neck. Cancers of the head and neck can arise anywhere in 
the upper aerodigestive tract and are categorized further by the area in which they begin. The 
regions can be seen in Figure A and include: the oral cavity, the larynx, the paranasal sinuses 
and nasal cavity and the pharynx, divided into three parts: the nasopharynx, the oropharynx, 
and the hypopharynx. 
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Figure A. Head and neck cancer regions.  
      Source: The website of the National Cancer Institute (http://www.cancer.gov) 
 
 
      1.1.2.  Risk Factors for HNSCC 
 
Alcohol and tobacco use are the two most important risk factors for HNSCC cancers 
(3,4). Infection with human papillomavirus (HPV), especially serotypes 16 and 18 (5) is a 
risk factor, particularly for oropharyngeal cancers (this region involves the base of the tongue 
and the tonsils) (6,7). In the U.S., incidence of oropharyngeal cancers caused by HPV 
infection is rising, while oropharyngeal cancers caused by other risk factors is declining (6). 
There have been both retrospective and prospective studies done that give evidence of a more 
favorable prognosis for HPV-positive oropharyngeal cancer patients when compared to 
patients with an HPV-negative status (8,9).  
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This may be due to an over expression of p16, shown to be associated with improved 
patient outcome (5,8).  The expression of the viral proteins E6 and E7, caused by an active 
HPV infection, will inactivate factors associated in DNA damage signaling and regulation of 
cell cycle, including p53 and RB, two essential tumor suppressors, and consequently inhibit 
feedback loop mechanisms, hence causing the over expression of p16 (10).  
 
      1.1.3  Treatments for HNSCC 
HNSCC patients primarily receive the following treatment options: surgical resection, 
external beam radiation, and/or chemotherapy (11,12). The most common drugs used are 
platinum-based (cisplatin) in combination with a cytotoxic agent (5-FU) (13,14). Treatment 
of HNSCC often requires multimodal therapy, with external beam radiation therapy as a 
primary method of treatment for advanced or locoregional disease.  As locoregional 
recurrence is the most frequent cause of death from HNSCC, the efficacy of radiotherapy in 
controlling this disease is critically important for patient survival.   
Unfortunately, even with the multitude of treatment options available for HNSCC 
patients, many still experience treatment failure leading to disease recurrence and metastasis. 
Some mechanisms of radioresistance have been proposed (15,16) yet relatively few 
biomarkers of radiosensitivity have been defined. There is a need for biomarkers that could 
help initially stratify HNSCC patients into those who may not benefit from radiation alone, 
but may need additional treatment. The following work aims to help identify the potential of 
defining TP53’s functional status as a predictive biomarker for selecting a patients treatment 
options. 
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1.2  Tumor Suppressor p53 
      1.2.1.  Description of the p53 Protein 
The p53 protein consists of 393 amino acids, having a molecular mass of 53kDa, and 
contains of five domains (Figure B).  The transactivation (TA) domain is located at the N-
terminal of the protein. It binds to several components including Mdm2, p53’s main negative 
regulator (17), the TATA-binding protein (TBP) and TBP-associated factors (TAFs), which 
control the transactivation capability of p53 (18-20). p53’s role in initiating apoptosis or cell 
cycle arrest is dependent on the control of its transcription (21,22). Upon radiation treatment, 
amino acids located in the transactivation domain are heavily phosphorylated, a clear 
indicator of p53 activation. The proline rich region lies next to the transactivation domain, 
and while its function has not been well characterized, it has been associated with mediation 
of both growth repressive and apoptotic functions (23). The DNA binding domain (DBD) is 
responsible for p53’s sequence-specific DNA binding activity. The DBD contains four 
evolutionarily conserved regions (24), where mutations of the amino acids within these 
regions have been recognized in over 90% of human cancers (25). Within the DBD lie the 
“hot-spot” mutations: R175H, G245S, R248W, R249S, R273H, and R282W.  These are the 
most frequently mutated six amino acid residues, which are essential in preservation of the 
structure of the DNA binding motifs (26).  The oligomerization domain, located at the C-
terminal of the protein, assists p53 molecules in forming tetramers, the optimized form for 
p53 to facilitate its activities (22).  The basic domain, also at the C-terminal, contains two 
nuclear localization sequences (27,28) and is an important part in p53’s recognition of 
damaged DNA (29). 
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Figure B. Protein domains of p53 
  
 
 
      1.2.2.  Functions of p53 
p53 is well known as the ‘guardian of the genome.’ It is a transcription factor that 
binds and transactivates genes to stimulate various cellular functions including apoptosis, 
autophagy, or cellular senescence (30). These cellular mechanisms are essential when it 
comes to protecting the cell against tumorigenesis. When DNA damage occurs, the DNA 
damage response (DDR) will activate p53 in an attempt to arrest cells from cycling, in order 
to allow sufficient time it initiating DNA repair pathways to correct the damaged lesions. If 
the damage is irreparable, p53 can trigger transcription of different pro-apoptotic genes to 
induce apoptosis, including Noxa and PUMA (p53-upregulated modulator of apoptosis) 
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(30,31). Alternatively, p53 can promote a senescence phenotype which is an irreversible cell-
cycle arrest, permanently halting damaged cell proliferation (32). The canonical downstream 
target of p53, p21, is critical in the initiation of cell cycle arrest because its deletion causes 
the cell to evade senescence (33,34).  
 
      1.2.3.  TP53 Mutation in Human Cancer 
Most tumor suppressor genes are altered by either deletions or truncating mutations, 
but p53 is unique because there is a preferred predisposition for missense mutations, 
predominantly involving amino acids in the DBD, as stated earlier. The presence of a 
missense mutation in tumor cells will most often lead to the stabilization and accumulation of 
p53 (35,36). A mutation is termed as a ‘loss of function’ if it causes the absence of 
expression of p53.Ssecondary to a dominant negative effect, a ‘loss of function’ could also 
refer to when a mutant p53 inhibits the remaining wild-type p53 allele. But, some missense 
mutations retain their expression, and can be considered ‘partially functional.’  It is also 
possible for a mutation of TP53 to be considered as a ‘gain of function’ mutation. This p53 
mutation can present with novel, oncogenic properties not seen when the activity of p53 is 
lost. Several examples of p53 ‘gain-of-function’ mutations have been identified and reviewed 
in (37).  
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      1.2.4.  TP53 Mutation in HNSCC 
TP53 has been shown to be the most common somatically mutated gene in HNSCC 
(38),  present in 40 - 60% of reported cases (39,40), with a majority of the mutations causing 
a disruption in the ability of the protein to transcribe genes important in regulating the cell’s 
response to DNA damage.  Two recent studies using whole exome sequencing of specimens 
from HNSCC have offered the most thorough examination of gene mutations concerning 
head and neck cancer, to date (38,41) and, not unexpectedly, TP53 mutations were, by far, 
the most common. It was also determined that loss of heterozygosity of TP53 occurred as an 
early event in development of HNSCC.  
Multiple studies have shown mutations in TP53 are associated with poor outcome 
(40,42,43). To address this point, several studies in HNSCC have relied on sequencing exons 
from the DBD of TP53 to assess for missense mutations (40,44). The functional status of p53 
has been shown to be a significant predictor of response to chemotherapy (45,46). Many 
prognostic parameters have been used to evaluate p53’s functional status in a tumor, such as: 
location-based classifications (24,44,47,48), type of amino acid change (49), and post-
translational modifications (50-53).  To evaluate the impact of the TP53 missense mutations 
used for this study, we have developed the Evolutionary Action (EAp53) scoring system 
(54). This system is a combination of two components: 1) the Evolutionary Trace (ET) 
approach, in which each sequence position is given a score that has been calculated to have a 
quantified impact on protein function based on evolutionary divergence data (55), and 2) the 
type of amino acid change at that position.  
 
8	  
	  
       1.2.5.  p53 and ROS 
In cells that are unstressed, p53 is maintained at minimal levels by ubiquitylation via 
Mdm2, with subsequent degradation by the 26S proteasome. Physiological and hyper-
physiological levels of p53 employ altered effects on the cell’s redox status through two well 
established mechanisms, either directly regulating antioxidant and pro-oxidant gene 
expression or by modifying cellular metabolic pathways. 
p53 overexpression activates a series of p53-induced genes (PIGs). Multiple PIGs 
encode redox proteins such as: proline oxidase (POX, PIG6) (56) and quinone 
oxidoreductase (NQO1, PIG3) (57), two ROS generating enzymes. Upregulation of POX and 
NQO1 leads to elevated oxidative stress and apoptosis. Several more p53-induced pro-
oxidant genes have been identified. These include p66Shc, BAX, and PUMA. BAX and 
PUMA induce mitochondria uncoupling, causing an increase of ROS generation from the 
electron transport chain (ETC) (43). 
Keeping ROS at non-toxic levels is a critical function of p53, which is regulated by 
its activation of antioxidant genes (58,59). At basal levels, p53 is necessary in maintenance 
of antioxidant gene transcription, including glutathione peroxidase-1 (GPX1), mammalian 
sestrin homolog (SESN1), and SESN2 (43). p53 suppression resulted in a decrease in the 
transcription of these genes leading to an elevation of ROS and therefore, oxidative DNA 
damage. Regulation of antioxidant defenses could be considered one of the many tumor 
suppressing activities of p53.  
Physiological levels of p53 are crucial to the activation of several metabolic enzymes. 
This allows p53 yet another responsibility: balancing energy metabolism. Mitochondrial 
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respiration is known as the major producer of intracellular ROS. Approximately 1–2% of the 
electrons leak out of the electron transport chain and these electrons form ROS (60). p53 
levels are fixed to normal mitochondrial respiration through its target genes, synthesis of 
cytochrome c oxidase 2 (SCO2), phosphoglycerate mutase (PGM), and TP53-induced 
glycolysis and apoptosis regulator (TIGAR) (61,62).  
 
1.3   An Introduction to p21 
The CDKN1a gene is localized on chromosome 6p21.2 and encodes a 21 kDa protein. 
This gene was discovered by three independent groups, each named it for the functions in 
which they observed: cyclin-dependent kinases (CDKs)-interacting protein 1 (CIP1) (63), 
wild-type p53-activated fragment 1 (WAF1) (64) and senescent cell derived inhibitor 1 
(SDI1) (65). Therefore, p21Waf1/Cip1/Sdi1 has been known from its origin to be a protein 
associated with p53, cell cycle arrest, and senescence. 
 
 
       1.3.1.  p21 and Cell Cycle Arrest 
Upon exposure to growth stimuli, CDKs: CDK2, CDK4 and CDK6, are successively 
activated during the cell cycle, and this leads to cell proliferation. p21 is primarily known as 
a CDK inhibitor. It is a member of the CIP/KIP family, which includes p57Kip2 and p27Kip1, 
as well.  They are all capable of inhibiting a broad spectrum of CDKs involved in cell cycle 
progression and therefore inducing an immediate arrest in different phases of the cell cycle 
(66). p21 was originally found in cyclin A, cyclin D1, cyclin E and CDK2 
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immunoprecipitates (63). It was determined that p21 arrested cells by affecting the activity of 
cyclin A, D, and E, via inhibition of binding to their respective kinases. This causes an 
inhibition of both G1 phase of progression through the cell cycle and initiation of DNA 
synthesis (67). pRB is essential for the G1/S transition and is released from complexes with 
E2F transcription factors upon the binding of cyclin D to CDK4/6. E2F’s are able to 
transactivate genes necessary for entry into S phase. The association of p21 with cyclin D-
CDK4/6 inhibits pRB phosphorylation and thus causes G1 cell cycle arrest (68). Finally, it 
has also been reported that p21 can arrest cells in the G2 phase of the cell cycle due to the 
ability of p21 to inhibit both binding of the cyclin A-CDK1/2 and cyclin B-CDK1 complexes 
(69). Additionally, p21 cooperates with 14-3-3 σ, which sequesters cyclin B-CDK1 
complexes in the cytoplasm, and thus inhibiting the G2 -M transition (70). 
When DNA damage occurs to normal proliferating cells, there is a temporary pause in 
the cell cycle at either the G1, S, or G2 phase. This is due in part to p53-dependent p21 up-
regulation in the presence of unrepaired DNA.  These checkpoints hinder DNA replication 
and mitosis while allowing time for DNA repair. There are multiple factors that determine 
the proportion of cells that arrest in G1, S, or G2 after DNA damage, such as: type of 
damage, growth conditions, cell type, and the functioning checkpoints in the cells. p21 can 
definitely be considered an integral part of p53-induced cell cycle arrest, based on the fact 
that, after DNA damage, p53 cannot arrest cells in p21-null mice (64). Additionally, 
depending on the level and type of stress, this arrest can cause the cell to enter a permanent, 
terminal state of differentiation known as senescence.  p21’s role as primary regulator 
senescence was established when its expression increased in human fibroblasts undergoing 
replicative senescence (65). 
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       1.3.2.  Transcriptional Regulation of p21 
p53 binds with high affinity to the p21 promoter this region contains two highly 
conserved p53-responsive elements. External stress signals, such as oxidative stress and 
DNA damage, and oncogenic and intrinsic stresses will activate p53 causing transcriptional 
up-regulation of p21. p21 expression can be induced by other transcription factors, in a p53-
independent manner (Figure F). There are several DNA-binding elements in the proximal 
p21 promoter region.  For example, the six Sp1/Sp3 binding sites which, in response to 
stresses and stimuli, such as: pRb, nerve growth factor (NGF), TGF β, phorbol myristate 
acetate (PMA), butyrate, and over-expression of the integrinβ1 subunit, are used to regulate 
p21 expression.  HDAC inhibitors are well established inducers of p21, as discussed in the 
next section.   
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Figure C. Extracellular signals that activate transcription of the p21 gene. 
Source: Transcriptional Regulation of the p21(WAF1/CIP1) Gene. Andrei L. Gartel and 
Angela L. Tyner. Experimental Cell Research 246, 280–289 (1999) 
 
 
 
       1.3.3  p21- An Effector of Gene Transcription 
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Even though p21 is not a transcription factor, it acts as a transcriptional cofactor, with 
some of its interactions having effects on gene expression and DNA-binding proteins.  As 
discussed earlier, p21is able to indirectly inhibit E2F1 factors, by dephosphorylation of pRB 
after CDK inhibition. Also, p21 can bind other transcription factors such as STAT3 and Myc, 
therefore inhibiting their transcriptional activity (71,72).  p21 can stimulate NF-κB-mediated 
transcription through the activation of cofactors p300 and CBP (73).  cDNA array 
hybridization, by Chang, et al. (74) revealed that p21 has the ability to induce the expression 
of 55 genes and the repression of 77 genes.  p21 is also associated with antioxidant pathway, 
in that it inhibits the binding of Nrf2 with its negative regulator, Keap-1, allowing for the 
inhibition of Nrf2 degradation (75).   
 
       1.3.4.  HDAC and Sodium Butyrate 
The primary function of histone acetylation is to alter the compaction of chromatin 
(76). It was suggested that acetylation of core histone tails obstructs interactions with DNA 
and/or proteins and thus destabilizes chromatin organization (77,78). The combined effects 
of histone acetylation on the disruption of chromatin structure is what enables transcription 
(79). The balance of acetylated histones is directed by the net activities of histone deacetylase 
(HDAC) and histone acetyltransferases (HATs). The expression of only 2% of mammalian 
genes is affected when HDAC activity is altered (80).  
There are three classes of HDACs. Class I includes the mammalian HDAC1, 2, 3 and 
8. Class II consist of mammalian HDAC4, 5, 6, 7, 9 and 10. Class III are members of the 
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sirtuin family (81-83). Butyrate inhibits most HDACs except class II HDAC6 and 10 and 
class III HDACs. 
Sp1 and Sp3 are ubiquitously expressed transcription factors that function as either 
repressors or activators (76). There is a butyrate response element within the promoter of 
butyrate-responsive genes (69,84). The p21 promoter has six Sp1 binding sites (considered to 
be the butyrate response element).  A condensed chromatin structure and an inactive p21 
promoter are due to the low steady-state level of acetylated histones associated with the p21 
promoter (85). The use of sodium butyrate to inhibit HDAC activity allows the HAT activity 
of p300 to elevate the level of histone acetylation at the promoter. This histones 
hyperacetylation encourages chromatin opening, induction of p21 gene expression and 
therefore inhibits cell proliferation, independent of p53 (86). 
 
1.4 Senescence  
       1.4.1.  Establishment of Senescence  
It was over 40 years ago when Hayflick defined senescence as an irreversible state of 
arrest of the cell cycle in which normal cultured diploid cells had lost their proliferation 
capacity (87).  This cell state was termed, “replicative senescence”, due to the ability of their 
incapacity to reach in vitro confluence.  Characteristics of these cells are a large, flattened 
morphology, multinucleation, high granularity and resistance to apoptosis (88). Cells in a 
senescent state display a distinct pattern of metabolic activity, with alterations in the 
expression of genes such as ATM/ATR, Chk1/Chk2, Rb, p16, p53, and p21 (89-91). Some 
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have also observed alterations in genes coded by mitochondrial DNA, such as ribosomal 
RNA 16S and the subunit-I gene of NADH dehydrogenase (92), which is elevated during 
senescence.  
 
       1.4.2. Types of Cellular Senescence 
Replicative cellular senescence refers to the propagation of human cells in culture 
that, over time, acquire shortened telomeres causing a disruption to their protective structure. 
Because DNA polymerase fails to replicate its lagging strands, telomeres are subject to 
erosion and when a critical length is reached, DNA damage response is triggered. ATM and 
ATR are activated, along with gamma-H2AX and p53 (93). And again, depending on the 
level of DNA damage, cells will either undergo apoptosis or senescence. How a cell decides 
its fate under these circumstances has remained ambiguous, but there are certain factors, such 
as cell type, the intensity and extent of the exogenous signal, as well as the nature of the 
damage, that are likely to be important deciding factors (94). In addition to p53, replicative 
senescence is connected to another tumor suppressor, Rb and its partner p16. In a number of 
cell lines, activation of both the p53/p21 and Rb/p16 pathways are essential for establishment 
of senescence, but the contribution of each of these signaling pathways to senescence 
depends on the cell line.  
To determine how dependent replicative senescence was on telomere shortening, 
ectopic expression of the telomerase holoenzyme (hTERT), which elongates telomeres, was 
used and not only abrogated the effect of the lack of end replication, but allowed these cells 
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to bypass senescence (95). Tumor cells often express telomerase (96), or are able to elongate 
their telomeres through alternative lengthening (97). Therefore, telomeres of cancer cells are 
sustained at a length that allows for continued proliferation (98). 
 A variety of conditions can induce senescence independent of the absence of any 
measureable telomere loss or dysfunction. This type of senescence has been termed- 
premature cellular senescence, since it arises prior to a stage induced by telomere shortening. 
The two types of premature cellular senescence are discussed below. 
 Oncogene-induced senescence (OIS) was shown when studies using mutant 
HRAS (HRASV12) led to cell cycle arrest upon its introduction into primary cells. This was 
surprising, given that HRAS is known to transform immortal mammalian cell lines and work 
together with immortalizing genes to oncogenically transform primary cells (99). These non-
proliferating cells phenotypically resembled those having replicative senescence, and this 
phenomenon become known as OIS. OIS can be distinguished from replicative senescence 
because OIS cells cannot be bypassed when hTERT is expressed (100).  
 Stress-induced senescence can result from inadequate culturing conditions leading 
to a culture shock. Cells removed from an organism and put into culture must acclimate to an 
artificial environment, which is characterized by atypical concentrations of nutrients and 
growth factors, ambient O2 levels, and the lack of extracellular matrix components and 
surrounding cell types (101). A stress-induced, accelerated senescence encompasses the cells 
induction of replicative senescence in respect to activation of the DDR in response to 
chemotherapeutic drugs or radiation.  
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       1.4.3.  Cancer Cells and Senescence 
Through the process of carcinogenesis, tumor cells have adapted mechanisms to 
avoid senescence. Such inhibitory events include: inactivation of p53 or Rb, two of the most 
commonly disabled tumor suppressor in cancer (which can be achieved through inhibition of 
papillomavirus oncoproteins E6 and E7) and an up-regulation of telomerase. Interestingly, 
most tumors not only have these senescence suppressing attributes, but also exhibit traits that 
promote senescence. Some examples are overexpression of mutant forms of Ras of Raf, 
shortened telomeres, and upregulation of mitogenic factors such as E2F1 (102,103). 
 Being aware of the mechanisms in which cancer cells avoid senescence offers 
opportunities to manipulate the cells such that they are driven to senescence, inhibiting their 
growth.  Inhibition of high risk E6 or E7 expression individually, or with expression of E2 
(negative regulator of both E6 and E7), or with siRNA targeting E6 and E7 mRNA was 
shown to rapidly promote senescence in multiple cervical cancer cell lines (104-107).  Also, 
with the forced expression of tumor suppressors such as p53 (108), Rb (109), p21 (110), p16 
(111), p57 (112), IGFBP-rP1 (113) cancer cells will progress to senescence.  Beyond altering 
cells in culture to develop into a senescent state, clinical treatment of cancers with various 
agents, generally those that affect DNA structure, such as cisplatin, doxorubicin, ionizing 
radiation and etoposide, are also able to readily force tumor cells into senescence (114). 
 As mentioned earlier, cancer cells exhibit a common characteristic of high levels of 
telomerase. While this does not lead to long telomeres, they are still maintained at a length 
that allows for continued proliferation (98), indicating that telomere stability may be required 
to avoid senescence. To investigate questions as to what other effects high telomerase 
activity could have in a tumor cell, if not to elongate telomeres, Blackburn, et al. knocked 
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down telomerase RNA causing a decrease of telomerase enzymatic activity and a depletion 
of telomerase ribonuleoprotein (115). The result was an immediate cease of the proliferation 
of telomerase positive cancer cells in combination with diminished expression of 73 genes 
including those associated with cell cycle progression (cyclin G2 and CDC27) or promoting 
tumor metastasis (integrin αV) as shown in (116). 
 Telomerase activity is complex and its regulation involves control at multiple levels 
including protein phosphorylation, protein- protein interactions and gene transcription (117). 
Both tumor suppressor and oncogenes have been associated with the regulation of telomerase 
activity either directly or indirectly, including c-myc, p53, p21, pRb and Akt (118-121). In 
addition, HeLa, colorectal cancer, and ataxia-telangiectasia cells have all been shown to have 
a dose dependent decrease in telomerase activity after ionizing radiation which was 
proportionate to cell death and tumor regression (122). This data suggest that another 
mechanism through which radiation induces senescence is through modulation of telomerase 
expression. 
. 
 
 
 
       1.4.4.  Biomarkers and Mechanisms of Cellular Senescence 
Induction of cellular senescence is initiated by a wide variety of conditions. Senescent 
cells display several characteristics that allow for their identification. Figure E, lists some of 
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these biomarkers that would indicate the activation of the mechanisms that contribute to the 
senescence program, such as the induction of tumor suppressor networks. 
 
 
        1.4.4a. Cell Cycle Arrest and Senescence-associated Heterochromatin  
                     Foci (SAHF) 
Permanent exit from the cell cycle is the principal marker for all types of cellular 
senescence. Heterochromatin structures, categorized as senescence-associated 
heterochromatin foci (SAHF’s), and multiple other factors contribute to keep cells in a 
senescent state. An altered chromatin structure is another characteristic of Cellular 
senescence.. DNA dyes display a homogenous staining in cycling or quiescent cells, but 
senescent cells, on-the-other-hand, show an extremely different, punctate staining pattern. 
Senescent cells also have an increased binding of heterochromatin-associated proteins, such 
as HP1γ, in the promoters of several E2F target genes (123). It has also been shown that 
interference with expression of genes encoding p53, C/EBPb, or IL-6 can reduce SAHF-
positivity, leading to abrogation of senescence (124,125). 
 
 
 
 
      1.4.4b.  Morphology Transformation and Senescence-associated beta- 
                   galactosidase (SA-β-gal) Activity 
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Cell senescence is accompanied by very distinct morphological changes, becoming 
large, flat, and multinucleated. Senescence-associated beta-galactosidase (SA-β-gal) is a 
commonly used senescence biomarker (126). Its increased activity in senescent cells derives 
from the enzyme, lysosomal b-D-galactosidase, encoded by the GLB1 gene. It is important to 
note that non-senescent cells also display SA-β-gal activity in the lysosomal compartment, 
but it is most functionally optimal at pH 4 (127). To circumvent this, the assay is prepared in 
a solution at pH 6, in which only senescence cells should be expressing this enzyme. The 
measurable increase of SA-β-gal activity seen in senescent cells is attributed to an 
enlargement of the lysosomal compartment, thus allowing for an increase in β-galactosidase 
activity (128). 
 
       1.4.4c.  Activation of Tumor Suppressor Networks 
The signaling pathways known to be activated during and while establishing a cells’ 
senescent state are the same for both replicative and accelerated senescence in response to 
DNA damage. The p53/p21 and Rb/p16 signaling pathways commonly facilitate the 
activation of the senescence program (129).  In human fibroblasts undergoing either 
premature or replicative senescence, p53 displays increased activity (130) and Rb 
accumulates in its active, hypophosphorylated form (131). p53 initiates prosenescence 
signals arising from spontaneous oncogene activation, DNA damage, telomere dysfunction, 
and elevated ROS. Protein kinases ATM and ATR are directly, or by activation of DNA 
damage kinases Chk1 and Chk2, in control of the phosphorylation of p53 leading to the 
activation of p21 and the inhibition of Cdks. Concurrently, the inhibition of Cdks leads to the 
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prevention of the activation of the E2F target genes and allows for a halt in the cell cycle 
(132). Other proteins in the Rb/p16 and p53/p21 pathways, notably p15 14-3-3σ and 
GADD45, also accumulate in senescent cells, and are used as signaling markers for the 
activation of these pathways in senescence (99,133,134). 
   
       1.4.4d.  ROS 
ROS contribute to induction of senescence, as demonstrated by its delayed onset 
when treated with antioxidants or its premature onset when treated with inhibitors of oxidant 
scavengers (43,135). An investigation into the maintenance of a senescence-like arrest when 
cells were exposed to a temporary expression of SV40 LT, revealed that ROS and Protein 
Kinase C functioned in a positive feedback loop in order to maintain this termination of 
proliferation (136). Additionally, ROS have been shown to impact either directly or 
indirectly on the p53/p21 and Rb/p16 signaling pathways. For example, ROS activation of 
the MINK–p38–PRAK pathway leads to senescence and controls the activation of p16, p53, 
and expression of p21, in a p53-independent manner (137). Although ROS certainly play a 
significant role in senescence, the way in which it contributes to this mechanism of cell death 
remains largely ambiguous. 
 
 
 
       1.4.4e.  Senescence Associated Secretory Phenotype (SASP) 
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Even though senescent cells are incapable of dividing and resistant to mitogenic 
stimuli, they remain metabolically active. It is suggested that they remain in this state, so that 
if the environment became stressful, they are still capable of activating genes related to 
extracellular matrix components, proinflammatory cytokines, proteases and growth factors 
(138,139). This phenotype is termed senescence associate secretory phenotype and is 
characterized by changes in the production of substances that act within the cell and are 
excreted to surrounding cells. The concern is that once these secreted substances act on 
nearby cells, they might contribute to the aging process or to the possible progression of 
diseases (140).  
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Figure D. A list of senescence biomarkers. SAHF, senescence-associated heterochromatin 
foci, DDR, DNA damage response; SASP, senescence-associated secretory phenotype; IL, 
interleukin; SMS, senescence-messaging secretome.  
Adapted from: Assessing Cell and Organ Senescence Biomarkers.  Bernardes de Jesus. 
Circulation Research. Vol. 111 no. 197 
 
 
 
 
 
 
1.5 Reactive Oxygen Species 
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      1.5.1  ROS Production and Elimination 
Multiple catabolic and anabolic processes, including aerobic respiration, form ROS as 
a by-product (Figure C) (141). Fatty acyl-CoA oxidase, xanthine oxidase, cyclooxygenases, 
cytochrome p450 systems and lipoxygenases are a few enzymes that produce ROS by-
products (142,143). NADPH oxidases, whose catalytic subunits are encoded by Nox 1–5 and 
Duox 1–2, can directly produce ROS from oxygen (144).  
Malic enzymes catalyze the oxidative decarboxylation of malate to pyruvate and 
NAD(P)H (145). NAD(P)H is necessary for the synthesis of ATP during oxidative 
phosphorylation. The inefficient transfer of electrons during this process could result in the 
generation of ROS (61). It has been shown that p53 inhibits the NADPH producer glucose-6-
phosphate dehydrogenase (146). Further investigation determined that downregulation of 
malic enzymes, ME1 and ME2, via suppression of MDM2 and ROS-induced AMPK 
activation, respectively, created a feedback loop allowing for the stabilization of p53, and 
that p53’s activation kept ME1 and ME2 levels inhibited through binding to their response 
elements, resulting in senescence (147). The p53-malic enzyme positive feedback loop is 
predominantly relevant when a persistent, active p53 activation necessary, such as in the 
initiation and maintenance of senescence. 
ROS levels are measured by their production, in combination with their rate of 
degradation.  This balance between ROS production and degradation is termed cellular 
homeostasis. Cells have developed multiple ways to defend against ROS; these include 
enzymatic and non-enzymatic antioxidants. Two examples of non-enzymatic antioxidants are 
glutathione (GSH) and thioredoxin (148).  After GSH is oxidized, the reduced form can be 
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regenerated by GSH reductase (Figure C). It is this balance between GSH and GSSG that can 
be used as a determinant of the redox state within the cell. 
Antioxidant enzymes act together with the non-enzymatic antioxidants to eliminate 
the ROS produced by reactions creating free radicals (Figure D). Superoxide dismutase 
(SOD) searches for the superoxide radical, produced by the respiratory chain, converting it 
into oxygen and hydrogen peroxide. In mammals, there are three types of SOD’s: the 
cytoplasmic, SOD1, the mitochondrial Mn-dependent, SOD2, and the secreted, Cu/Zn-
dependent SOD3 (Figure C) (149). Conversion of hydrogen peroxide into water is performed 
by the peroxidases and catalase (150,151).  
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Figure E. A schematic of cellular redox homeostasis. The mitochondrial electron transport 
chain (Mito-ETC), the endoplasmic reticulum (ER) and the NADPH oxidase (NOX) complex 
are major sites of cellular ROS production. . GPX, glutathione peroxidase; GR, glutathione 
reductase; GRXo, glutaredoxin (oxidized); GRXr, glutaredoxin (reduced); GSHr, glutathione 
(reduced); GSSG, glutathione (oxidized); TRXo, thioredoxin (oxidized); TRXr, thioredoxin 
(reduced); XO, xanthine oxidase.  
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery 
(Dunyaporn Trachootham, Jerome Alexandre, and Peng Huang. Targeting cancer cells by 
ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug 
Discovery 2009 8(7):579-9. 
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Figure F. Electron structure of common reactive oxygen species.  
Source: http://www.biotek.com/resources/articles/reactive-oxygen-species.html 
 
       1.5.2.  ROS Regulation of Signaling Molecules 
ROS are able to control the expression of many signaling proteins and transcription 
factors involved in the cell survival and stress response (152). Several redox sensitive protein 
tyrosine phosphatases and protein tyrosine kinases have been discovered. Some examples of 
kinase activity regulation by a redox-regulated phosphatase are: the inactivation of Jun kinase 
being abrogated by the oxidation of the MAPK phosphatase (144) and the up-regulation of 
the kinase activity of PTEN upon its oxidation (153).  ROS can also influence the 
transcriptional activation of select genes.  Transcription factors known for their participation 
in the cell’s oxidative stress response have been shown to also be a part in developmental 
processes. For example, NFκB is activated in response to ROS elevation (154). NFκB 
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activation can be associated with the antioxidant response, being that SOD2 and thioredoxin 
are some of its target genes (155). 
Various growth factors having mitogenic activity can activate signaling pathways in 
order to promote the production superoxide and hydrogen peroxide. Some examples of these 
growth factors are: epidermal growth factor (EGF) (156), platelet derived growth factor 
(PDGF) (157), transforming growth factor (TGF) (158), and fibroblast growth factor (FGF) 
(159). The addition of low levels of either superoxide or hydrogen peroxide will increase 
proliferation of smooth muscle cells (160), fibroblasts (161), amnion cells (162), and aortic 
endothelial cells (163).  Osteoclast differentiation is modulated by ROS, by which Rank 
ligand stimulation of bone marrow monocyte-macrophage lineage activates NADPH oxidase, 
creating transient increases the intracellular level of ROS (164). In endothelial cells, ROS 
have been shown to contribute to vascular endothelial growth factor (VEGF) and PDGF-
induced phosphorylation of MAPK’s, Akt, and Erk1/2 (165). Also, the induction of 
angiogenesis by VEGF expression, can be prompted by Nox1 (166). 
 
       1.5.3.  ROS and Cancer 
 
 
There is a large amount of evidence showing various cancer cell types have elevated 
ROS levels, compared with their normal counterparts (167-169). For example, leukemia cells 
that from patient blood samples showed higher ROS levels when compared with normal 
lymphocytes (170). Multiple intrinsic and extrinsic factors have been shown to induce 
oxidative stress during cancer development and progression. Some intrinsic factors are 
mitochondrial dysfunction, loss of functional p53, activation of oncogenes, and aberrant 
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metabolism (171-173). Genes associated with tumor transformation, such as Ras, c-Myc, and 
Bcr-Abl and were able to elevate ROS production after their expression (174). For example, 
when NIH3T3 fibroblast cells were transformed with H-Rasv12, an increased level of 
superoxide was produced through activation of the ROS-generating enzyme NADPH oxidase 
(NOX) (175). Cancer cells generally display genetic instability at an advanced disease stage. 
This causes a significant increase in ROS production, due in part to a ‘vicious cycle’, 
considered to be when ROS induce gene mutations causing further metabolic malfunction 
and ROS generation (176). 
  A moderate elevation in ROS can promote cell differentiation and proliferation 
(177,178), as discussed previously, while excess amounts are able to cause oxidative damage 
to DNA, proteins, and lipids (179). Therefore, maintenance of ROS homeostasis is vital for 
standard cell growth and survival. Oxidative stress is defined as a disruption of redox 
homeostasis because of a decline of ROS-scavenging or an elevation of ROS production 
(169). Significant to the initiation and progression of cancer, is the increase of ROS 
(180,181).  Elevated ROS also relates to the level of aggressiveness of a tumor and to a 
patients’ poor prognosis (182). Yet, as cancer cells have developed a sustainable environment 
of elevated oxidative stress, it has been suggested that they would have a greater dependence 
on antioxidants for survival (183). Therefore, controlling ROS levels by redox modulation 
may be a way to selectively kill cancer cells, avoiding a significant amount of toxicity to 
normal cells (184).  
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       1.5.4.  Cancer Cells’ Adaptation to ROS Stress  
Genomic instability developing from genetic or epigenetic alterations of numerous 
genes can amass during cancer development without distinctly changing the cell’s phenotype. 
This allows for  ‘silent’ adaptations until survival advantage can be achieved in the tumor 
microenvironment (185). Choi, et al showed that when normal epithelial cells  were exposed 
to low and continuous levels of oxidants the cells created a resistance to further oxidative 
stress, even when treated at a higher level (186). This suggests that cells are able to adapt to 
alterations in cellular redox capabilities in order to survive under a certain amount of 
oxidative stress.  Another example shows that in response to ROS stress, cancer cells respond 
by increasing their VEGF levels, by activating HIF-1, thus inducing angiogenesis (187). 
Overall, we can see that in the presence of long term intrinsic oxidative stress, cancer 
cells have developed an enhanced antioxidant capacity, seemingly making them resistant to 
exogenous stress (188-190). Cancer cells that have become well-adapted to this intrinsic 
oxidative stress have acquired mechanisms that upregulate ROS-scavenging systems to 
adjust to the stress and inhibit apoptosis. These adaptations may assist in contributing to the 
cell’s malignant transformation, metastasis and resistance to anticancer drugs (191-193). In 
order to efficiently kill cancer cells and surmount the drug resistance related to their redox 
adaptation, it is of the utmost importance to fully understand the modifications these cells 
have created and their core mechanisms. 
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       1.5.5.  PEITC 
Dietary isothiocyanates are naturally occurring compounds that have become of 
interest in the field of cancer research because of their potential as chemopreventative cancer 
agents (194). β-phenylethyl isothiocyanate,  PEITC, is a member of this class of compounds. 
The mechanism by which PEITC exhibits its growth inhibitory actions is wide ranging and 
clearly cell type dependent. For example, it has been reported that PEITC can induce 
apoptosis in the human colorectal carcinoma cell line, HT-29, not only by mitochondrial 
release of cytochrome c but also by activation of caspase-9 and -3, leading to activation of 
JNK (195). In a later publication (196), this same group, using the same HT-29 cell line, in a 
similar concentration range of PEITC, showed that PEITC’s ability to induce apoptosis is 
complementary to its ability to cause the down regulation of cyclins A, D, and E through 
activation of the p38 MAPK pathway resulting in G1 cell cycle. In prostate cancer cells, 
PEITC inhibited nuclear factor kappa B (NFκB) transcriptional activity, NFκB regulated, 
VEGF, along with cylcin D1, and Bcl-XL expression (197). NFκB has been linked to 
progression and survival of cancer cells, as well as inflammation, (73), so it is a significant 
molecular target of PEITC.   
PEITC is most recognized for its effect on decreasing glutathione (GSH). 
Trachootham, et al. designed an experiment demonstrating that oncogenically transformed 
cells were more sensitive to ROS-mediated damage compared to their unaltered isogenic 
partner cell line (198). She proved that treatment with PEITC was more effective in these cell 
lines due to their high basal ROS level. They created two sets of isogenic cell lines: one set in 
hematopoietic cells harboring a tetracycline-inducible Bcr-Abl expression vector and the 
other set using a previously immortalized normal ovarian epithelial cell line transfected 
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with H-RasV12. Since the Ras or Bcr-Abl transformed cells depended on GSH to counteract 
the elevated ROS, the severe effect of PEITC on the abrogation of GSH led to massive cell 
death. Their study showed that PEITC was able to elevate ROS by two mechanisms: through 
depletion of GSH by stimulating its export from the cell and through inhibition of glutathione 
peroxidase enzyme activity. 
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1.6  Hypothesis and Specific Aims 
Hypothesis: Long term expression of p21 and its ability to sustain elevated levels of 
ROS is dependent on wild-type or partially functional TP53 and are the key factors in 
establishment and maintenance of premature senescence in HNSCC.  
To test this hypothesis the following specific aims will be conducted: 
Aim 1: Examine p21 as an essential mediator in establishment and maintenance of 
senescence in HNSCC cells when treated with ionizing radiation.  
Aim 2: Establish a relationship among long term expression of p21, sustained 
elevation of ROS, and functional p53 in causing senescence in HNSCC cells.   
Aim 3: Show HN31’s partially functional p53 status will allow for sensitivity to 
persistent exposure to direct ROS, stimulating activation of the p53-p21 pathway, leading to 
an increase in senescence. 
Aim 4: Demonstrate that direct transcription of p21 or elevation of ROS, by 
suppression of antioxidant levels, can be therapeutic approaches to sensitize radioresistant, 
partially functional p53 cells.   
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Chapter 2: Methods 
Cell culture and constructs 
HNSCC cell lines HN30 and HN31, originated in our lab, and PCI-13, acquired from Dr. 
Jennifer Grandis (University of Pittsburg), were cultured in a 37˚C incubator in 5% CO2 
atmosphere and maintained in Dulbecco modified Eagle medium that contained fetal bovine 
serum, penicillin/ streptomycin, glutamine, sodium pyruvate, nonessential amino acids, and 
vitamins.  Cells infected with GFP tagged empty lentiviral vector (pLVTHM) or vector 
encoding a short-hairpin RNA (shRNA) against p53 (pLVUH-shp53, Addgene Inc., 
Cambridge, MA) were sorted using flow cytometry.  Cells infected with GFP tagged empty 
lentiviral vector (pGIPz) or vector encoding a short-hairpin RNA (shRNA) against p21 
(V3LHS_322234, Thermo Scientific, Pittsburgh, PA) were selected using puromycin. Wild-
type p53 construct was made by inserting  wild-type p53 cDNA into the pBABE retoviral 
vector with A161S or C176F mutations generated within wild-type p53 vector using site-
directed mutagenesis as described in (54). The wt, pBABE, A161S, and C176F vectors were 
used to infect PCI-13 cells, which underwent selection with puromycin. All cell lines used in 
this study have been authenticated against the parental recipient cell line via short tandem 
repeat analysis.  
 
Clonogenic assay 
HNSCC cells were seeded in 6-well plates at predetermined densities for radiation doses 
ranging from 2 to 6 Gy, to allow for an equal number of ensuing colonies. The next day, cells 
were irradiated using a high-dose-rate 137Cs irradiator (4.5 Gy/minute) and cultured for 8-10 
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days to allow for colony formation. Cells were then fixed in a 1.5% crystal violet/50% 
methanol solution. Colonies of more than 50 cells were counted and survival fraction was 
determined. All treatments were performed in triplicate. 
 
Senescence-associated-β-gal staining 
Senescence-associated β-gal staining was carried out according to the manufacturer’s 
instructions (Cell Signaling, Danvers, MA). Briefly, HNSCC cells were plated in 6-well 
plates and irradiated with 4 Gy on the next day. One hour prior to irradiation, N-acetyl 
cysteine (NAC) was added, and every 24 hours refreshed with new media containing NAC.  
Cells were cultured normally for 96 hours; they were then fixed for 15 minutes and stained 
overnight at 37˚C. Blue-staining cells were scored as senescent and reported as a percentage 
of all the cells observed per high power field. Other treatments concerning hydrogen 
peroxide or multiple doses of radiation are described in Results. Error bars represent standard 
deviation. 
 
Immunoblotting 
Cells were treated as indicated and washed once with cold PBS. Standard lysis buffer (199) 
was then added to each plate, and plates were incubated on ice. Cell lysates were then 
collected using a plastic scraper and centrifuged at 14,000 rpm at 4˚C for 10 minutes. The 
supernatant was removed, and total protein concentration was then calculated using the Bio-
Rad Protein Assay (Bio-Rad, Hercules, CA). Samples were prepared and immunoblot 
analysis was carried out as described previously (200). Briefly, membranes were blocked in 
36	  
	  
5% milk for 1 hour, then incubated overnight with anti-p53 DO-1 (Santa Cruz 
Biotechnology, Santa Cruz, CA ), anti-phospho p53 (Santa Cruz Biotechnology), anti-β actin 
(Cell Signaling), anti-p21 (BD Pharmingen, San Jose, CA), ME-1 (Santa Cruz), ME-2 (Santa 
Cruz), p16 (Santa Cruz), DDB2 (Cell Signaling), and Nrf2 (Santa Cruz) at 4˚C. Membranes 
were washed with 0.1% Tween 20 in TBS and incubated for 1 hour at room temperature with 
species-specific secondary antibody. Signal was generated using the Super-Signal West 
chemiluminescent system (Pierce Biotechnology, Rockford, IL). 
 
ROS measurement 
ROS levels were measured according to previously published protocols (201) using 5-(and-
6)-carboxy-20,70-dichlorofluorescein (CMH2-DCFDA) or dihydroethidium (DHE) dye 
(Invitrogen, Grand Island, NY). Briefly, cells were treated with irradiation, hydrogen 
peroxide or NAC as described in Results, then detached with 0.5% trypsin, washed with Ca-
/Mg- PBS, and resuspended in FACS tubes with PBS containing 5µM CMH2-DCFDA or 
DHE for 45 minutes.  Fluorescence measurements were then conducted using a Beckman 
Coulter XL 4 color cytometer and the data were analyzed using Flow-Jo software.  
 
Transient transfection 
The p21 cDNA was generously provided by Dr. Guangan He and generation of the Myc-p21 
vector is described in (202). Myc-p21 or empty vector was transfected into HN31 cells with 
Lipofectamine2000 (Invitrogen), per the manufacturer’s instructions. Cells were exposed to 
the transfection mixture containing .1µg of plasmid DNA for 5 hours, washed and then 
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replenished with normal media. At various time points, as described in Results, cells were 
collected either for FACS analysis after DCFDA preparation or for immunoblotting.  
 
RT-PCR 
Isolation of total RNA of p21 in HNSCC cells collected at the indicated timepoints after 4 Gy 
irradiation was determined using quantitative reverse transcription PCR. Reverse 
transcription was completed with the use of the iScript cDNA synthesis kit (Bio-Rad), per 
manufacturer’s instructions.   The 7900HT Real Time PCR Systems (Applied Biosystems, 
Foster City, CA) was used for quantitative real-time PCR, with Power SYBR Green PCR 
Master Mix (Applied Biosystems) using the following primers: p21 forward 5'-
CGCTAATGGCGGGCTG-3', reverse 5'-CGGTGACAAAGTCGAAGTTCC-3', GAPDH 
forward 5’-TGATGGTACATGACAAGGTGC-3’, GAPDH reverse 5’-
ACAGTCCATGCCATCACTGC-3’. Duplicate samples were used from two independent 
experiments, with the GAPDH gene used as an internal control. 
 
Population doubling level 
In order to generate the cumulative population doubling level (PDL), the increase in 
population doubling that was calculated was added to the PDL of the previous population 
using the equation below, adapted from	  (203): 
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HP1-γ staining 
HNSCC cells were detached with 0.5% trypsin, washed with Ca-/Mg- PBS, and resuspended 
in PBS. A final concentration of 4% formaldehyde was used to fix the cells for 10 minutes. 
Ice-cold 100% methanol was added by gentle vortexing to permeabilize the cells. Cells were 
spun down and counted such that 1x106 cells were used in each condition. Cells were blocked 
for 10 minutes at room temperature, then a 1:200 dilution of HP1- γ antibody was added for a 
2 hour incubation at room temperature. Cells were washed and incubated with goat-anti-
rabbit Alexa Fluor 594 fluorochrome-conjugated secondary antibody at a 1:1000 dilution, for 
30 minutes at room temperature. Cells were washed, resuspended in 500µl of PBS and 
Fluorescence measurements were then conducted using a Beckman Coulter XL 4 color 
cytometer and the data were analyzed using Flow-Jo software. 
 
Flank mouse model of PEITC treatment 
All animal experimentation was approved by the Animal Care and Use Committee (ACUC) 
of the University of Texas M.D. Anderson Cancer Center.	  1x106 Tu138 HNSCC tumor cells 
were suspended in 100ul of serum-free DMEM media and injected subcutaneously into the 
flank of 40 nude mice using a 25G needle. Seven to 9 days after the cells were injected the 
mice were randomly assigned into control and treatment groups for monitoring of tumor 
growth and metastasis. PEITC was administered directly at the base of the tumor 5 times per 
week (weekdays only) at a dose of 5mg/kg. Control mice were given 100µL of PBS by IP 5 
times per week. Mouse weight and tumor volume were examined twice a week. Tumor 
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volume was measured by calipers and volume was calculated as (A)(B2)π/6, where A is the 
longest dimension of the tumor and B is the dimension of the tumor perpendicular to A. Mice 
were euthanized if more than 20% of their preinjection body weight was lost, or if the 
ulceration of their tumor reached a level in which the veterinary staff required sacrifice. 
Tumors were fixed in formalin and embedded in paraffin for immunohistochemical and 
hematoxylin and eosin (H&E) staining done by our collaborators in Thailand. 
 
Statistics 
Student’s t-tests were carried out to analyze in vitro data. All P-values are 2-sided and error 
bars represent ±	   standard deviation. P-values less than 0.05 were considered significant. 
Tumor volumes for PEITC treated animals were determined using Bonferini post-test. Tumor 
area for PEITC treated animals were determined using One-way ANOVA. 
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Chapter 3: Results 
3.1 Examine p21 as an essential mediator in establishment and maintenance of  
senescence in HNSCC cells when treated with ionizing radiation  
3.1.1.  Null and mutant TP53 HNSCC cells are resistant to radiation-induced 
senescence when compared to HNSCC cells expressing wild-type TP53  
To evaluate the radiosensitivity of HNSCC cells varying in p53 status, an isogenic 
pair of HNSCC cell lines, derived from the same patient differing only in their p53 status, 
HN30 (wild-type TP53, wtp53) and HN31 (TP53 mutations, C176F and A161S) were used 
along with their p53 knockdown counterparts (HN30 shp53 and HN31 shp53). Clonogenic 
assays showed that the 4 Gy surviving fraction in TP53 null or mutant cells was significantly 
higher than in cells with wtp53 (Figure 1).  Being that senescence is the primary mechanism 
of radiation induced cell death in HNSCC cells (204), a senescence associated β-
galactosidase (SA-β-gal) staining was performed and showed that 4 days after treatment with 
4 Gy ionizing radiation, cells with wtp53 had a significantly higher SA-β-gal positive 
staining (60%) compared to the SA-β-gal positive staining in TP53 null and TP53 mutant 
cells (less than 5%) (Figures 2 and 3).  Another marker used to establish the senescent 
phenotype was heterochromatin protein 1 gamma (HP1γ), known to contribute to the 
maintenance of senescence –associated heterochromatin foci (SAHF). Figure 4 showed that 
96 hours after exposure to 4 Gy, there was an elevated level of HP1γ in the senescent HN30 
cell line when compared to the senescence resistant HN31 cell line.  These results indicated 
that cells expressing mutant forms of TP53 or are null for TP53 are relatively radioresistant 
when compared to isogenic cells expressing wtp53, and that this radioresistance was 
associated with a lack of radiation-induced senescence. 
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Figure 1. Null and mutant TP53 HNSCC cells are resistant to radiation when 
compared to HNSCC cells expressing wild-type TP53. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Null and mutant TP53 HNSCC cells are resistant to radiation-induced 
senescence when compared to HNSCC cells expressing wild-type TP53. 
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Figure 3. Quantitation of SA-β-gal positive senescent cells (those staining blue) from 
three independent experiments from four randomly selected fields in each well of cell lines 
show in Figure 2. 
 
 
 
Figure 4. Flow cytometric analysis showing HP1γ protein is elevated at 96 hours 
after 4 Gy radiation. 
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3.1.2. Loss of p21waf1/cif1 leads to a significant decrease of radiation-induced 
senescence in TP53 wild-type cells 
Two major pathways are associated with induction of premature senescence: p53-p21 
and Rb-p16. To distinguish if one or both of these pathways were active in the initiation of 
senescence in the wtp53 HNSCC cells, we first looked at the baseline level of p16 in all cell 
lines used for experiments within this thesis.  It has been reported that HN30 and HN31 cells 
have a mutation on the MST1/CDK41 gene, which encodes p16, rendering it inactive (205); 
while PCI-13 cells express a low copy number and methylated p16 status, also rendering it 
inactive (data not shown).  Figure 5 confirmed that the p16 protein was not expressed in 
these cell lines, using the HPV+ UMSCC47 cell line as a positive control.  
Next, to assess whether the decrease in radiation-induced senescence seen in null and 
mutp53 HNSCC cells, relative to wtp53 HNSCC cells, was due to the loss of p53 
transcriptional activity and induction of p21, we measured the expression of the p21 gene by 
qRT-PCR at various times after exposure to 4 Gy ionizing radiation.  As shown in Figure 6, 
HN30 cells had an elevated expression of p21 mRNA at both the 24 and 96 hour time point, 
while HN31 cells showed no elevation in p21 mRNA.  Western blot analysis demonstrated 
that long-term expression of the p21 protein in HN30 cells, with no expression in HN31 and 
TP53 null cells (Figure 7).   
In order to further establish a relationship between p53, p21, and senescence in wtp53 
HN30 cells, stable knockdown of endogenous p21 with lentiviral shp21 vector was 
performed  in this cell line (HN30 shp21; Figure 8), and then these cells were evaluated for 
their response to radiation.  Using a clonogenic survival assay, HN30 shp21 cells were found 
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to be relatively resistant to ionizing radiation when compared to HN30 Lenti control cells 
(Figure 9). Similar to null and mutp53 cells, this resistance was associated with a decrease in 
radiation-induced senescence, shown with use of SA-β-gal staining (Figure 10 and 11).  
Taken together these findings indicate that p21 plays a critical role in the therapeutic 
response of HNSCC cells to radiation.  
 
 
 
      
 
  
 
 
 
Figure 5. Western blot showing baseline p16 levels of HNSCC cell lines: PCI-13, 
HN30, HN31 and, as a positive control, UMSCC47. 
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Figure 6. quantitative RT-PCR analysis of p21 mRNA expression showing p21 
mRNA level is significantly elevated at both 24 and 96 hours after 4 Gy radiation in HN30 
cells, while there is no increase in HN31 cells. Error bars represent standard deviation of 
each sample performed in duplicate.  
 
 
 
 
 
 
 
 
Figure 7. Western blot showing p21 protein is elevated at both 24 and 96 hours after 
4 Gy radiation in HN30 cells, while there is no increase in HN31. HN30 shp53 or HN31 
shp53 cells. 
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Figure 8. Western blot showing successful stable lentiviral knockdown of p21 in 
HN30 cells via their lack of increased protein level 24 hours after 4 Gy. 
 
 
 
 
Figure 9. Clonogenic assay showing resistance to ionizing radiation in HN30 cells 
with knockdown of p21 when compared to Lenti control.  
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Figure 10. SA-β-gal staining showing.p21 knockdown cells are resistant to radiation-
induced senescence when compared to Lenti control. 
 
 
 
 
Figure 11. Quantitation of SA-β-gal positive senescent cells (those staining blue) 
from three independent experiments from four randomly selected fields in each well of cell 
lines shown in Figure 10.  
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3.2 Establish a relationship among long term expression of p21, sustained elevation of 
ROS, and functional p53 in causing senescence in HNSCC cells  
3.2.1. Transient expression of p21 in combination with ionizing radiation causes 
long-term p21 expression and elevated ROS, leading to a significant increase in 
senescence in HNSCC cells with mutp53 
Recent reports have shown that there is a strong correlation between p21, ROS, and 
senescence induction with results varying by stimulus and cell type (206-208). Since our 
mode of treatment for these HNSCC cells was ionizing radiation, we furthered our 
investigation into the p21-senescence relationship by measuring the effect that p21 
overexpression would have on ROS.  While the ROS produced from ionizing radiation do 
not have a direct effect on p21 transcription without the presence of TP53 (Figure 6), the use 
of DCFDA, a fluorescent marker of intracellular ROS, showed that transient overexpression 
of Myc-tagged p21 in HN31 cells significantly increased the amount of ROS produced by the 
cell at 24 hours. Importantly, as expression of the p21 protein went back to baseline at 96 
hours, so did the ROS levels (Figure 12). Furthermore, the combination of p21 
overexpression and radiation allowed for sustained elevation of ROS levels, when compared 
to either p21 overexpression or radiation alone (Figure 12).  
We next wanted to determine whether the effect of sustained ROS due to elevated 
p21 levels in combination with radiation could create sensitivity in HN31 cells, via the 
senescence mechanism seen in wtp53 cells.  During a 96 hour period, we monitored the p21 
protein level in HN31 cells having transient p21 expression alone or transient p21 expression 
in combination with 4 Gy ionizing radiation, given 24 hours after the initial transfection.  The 
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p21 protein level in cells with transient p21 expression in combination with radiation was 
sustained at a higher level at the later time points of 72 and 96 hours when compared to p21 
protein level in cells with transient p21 expression alone (Figure 13 and 14). Also, it was 
observed that the phosphorylation of p53 remained elevated in cells with the combination 
treatment of p21 expression and radiation. This indicated that the longevity of p21 in these 
cells, due to a radiation triggered temporary delay in proliferation (Figure 15), allowed for its 
prolonged effect of keeping ROS elevated, therefore, maintaining the cell in a stress 
stimulated state.  
Only in HN31 cells exposed to radiation and transient expression of p21 was there a 
significant increase in the percentage of senescent cells (Figure 16 and 17). Overall, these 
data suggest that p21 has a direct influence on ROS and that radiation treatment can enhance 
the sustained expression of p21, most likely through long-term, stress induced 
phosphorylation of p53, and that this relationship is necessary for the induction of 
senescence. 
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Figure 12. DCFDA staining showing ROS levels were significantly increased 24 
hours after transient transfection of p21 in HN31 cells, but return to baseline at 96 hours. 
However, ROS levels stayed elevated 96 hours after transient transfection in combination 
with 4 Gy.   
 
 
 
 
 
 
 
Figure 13. Western blot showing: endogenous p21 expression at early and late time 
points in HN30 cells exposed only to 4 Gy and, the extended stability of phosphorylated p53 
and p21 when HN31 cells are transiently transfected with p21 DNA in combination with 4 
Gy ionizing radiation when compared to transient transfection alone.   
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Figure 14. Quantification of the p21 protein level between treatment conditions at 
each indicated time point when compared to loading control, actin. 
 
 
 
 
Figure 15. Population doubling assay showing that the brief inhibition of 
proliferation of HN31 cells following ionizing radiation allows for the extended p21 stability 
in transfected cells. HN31 cells do recover their doubling capacity, confirming their 
radioresistance. 
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Figure 16. Left Column: HN31 cells were transiently transfected with the p21 DNA 
only; Right Column: 24 hours after transfection, cells were irradiated with 4 Gy. Cells 
receiving both p21 DNA and 4 Gy exhibit an increase in SA-β-gal staining. 
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Figure 17. Quantitation of SA-β-gal positive senescent cells (those staining blue) 
from three independent experiments from four randomly selected fields in each well of cells 
lines shown in Figure 16. 
 
 
 
 
 
 
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
no treat lipo only vector p21 
%
 se
ne
sc
en
t c
el
ls
 
HN31 cells  
no tx 
4 Gy 
54	  
	  
 
3.2.2.  Long-term elevated ROS in cells with wtp53 is dependent on p21  
Analysis of ROS levels using DCFDA dye revealed that HNSCC cells, regardless of 
p53 status, do have an initial burst of ROS 15 minutes after exposure to 4 Gy of ionizing 
radiation, albeit at a much higher level in wtp53 cells (Figure 18).  Treating these same cell 
lines with 4 Gy and following the ROS levels for an extended time course showed that the 
initial ROS burst in wtp53 cells was not only sustained but became significantly elevated at 
the 96 hour time point, when compared to the slight, non-significant increase seen in mutp53 
cells (Figure 19).  
 We then investigated the direct role of p21 on ROS sustainability. Being that HN30 
Lenti and HN30 shp21 cells were GFP tagged, it was necessary to find another fluorescent 
ROS indicator, other than DCFDA, that would measure outside the green spectra.  
Dihydroethidium (DHE) was used as a superoxide indicator which exhibits fluorescent red 
within the nucleus upon oxidation.  Figure 20 verified that cells with wtp53, but lacking p21 
(HN30 shp21) do not have long-term elevated ROS levels post-ionizing radiation compared 
to the HN30 Lenti control. These findings suggest that the ability of wtp53 cells to undergo 
radiation induced senescence is primarily due to p21 influence on the level of ROS produced 
by the cell. 
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Figure 18. DCFDA staining showing that HN30 and HN31 cells both exhibit an 
initial burst of ROS 15 minutes after exposure to 4 Gy. Error bars represent standard 
deviation of each sample performed in triplicate.  * P < 0.05 by Student’s t-Test 
 
 
 
 
 
 
 
 
 
Figure 19. Both HN30 and HN31 cells were exposed to 4 Gy and DCFDA staining 
shows that ROS are sustained at an elevated level up to 96 hours only in HN30 wild-type 
TP53 cells. Error bars represent standard deviation of each sample performed in triplicate.    
* P < 0.05, by Student’s t-Test 
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Figure 20. 96 hours after HN30 Lenti and HN30 shp21 cells were exposed to 4 Gy, 
use of the superoxide indicator, DHE, shows that the long-term sustained elevation of ROS in 
HN30 cells is largely due to p21. Error bars represent standard deviation of each sample 
performed in triplicate.  * P < 0.05, by Student’s t-Test  
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3.2.3. The use of antioxidants causes a significant decrease in the 
phosphorylation of p53, transcription of p21, and senescence 
To determine the impact of ROS in causing the senescence seen in wtp53 cells after 
treatment with ionizing radiation, HN30 wtp53 cells were treated with the antioxidant, n-
acetyl cysteine (NAC), two hours before exposure to 4 Gy and every 24 hours after, up to the 
96 hour time point at which the SA-β-gal staining was performed. Treatment with NAC 
allowed for the suppression of intracellular ROS and caused a significant decrease in the 
percentage of senescent cells after radiation exposure compared to wtp53 cells not receiving 
NAC (Figures 21 and 22). The use of DCFDA, confirms that daily treatment with NAC for 
96 hours inhibited ROS production after radiation (Figure 23). 
We were also interested to determine the effect that inhibition of ROS would have on 
the induction of p53, its transcriptional activation of p21 and p21’s sustainability of ROS to 
ensure a senescent phenotype.  HN30 cells were irradiated at 4 Gy, then 24, 48, and 72 hours 
later media was refreshed and supplemented with NAC. We observed that at the later time 
points of 72 and 96 hours, the ability of NAC to decrease ROS did indeed lead to decreased 
p53 phosphorylation and therefore a concomitant decrease in p21 (Figure 24). These data 
support the notion that increased ROS levels lead to p21 induction through the stress induced 
activation of p53 and that this pathway leads to senescence. 
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Figure 21. SA-β-gal positive staining showing that the radiation induced senescence 
seen 4 days after 4 Gy in HN30 wild-type TP53 cells can be prevented with use of the 
antioxidant N-acetyl cysteine (NAC). 
 
 
 
 
Figure 22. Quantitation of senescent cells (those staining blue from three independent 
experiments from four randomly selected fields of the cell lines shown in Figure 21. Error 
bars represent standard deviation. 
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Figure 23. DCFDA staining showing that the use of NAC everyday does inhibit the 
accumulation of ROS at the 96 hour time point, the time at which the SA-β-gal staining is 
performed. 
 
 
 
 
 
 
 
 
 
Figure 24. Western blot displaying a time course of the ability of NAC treatment to 
decrease p53 phosphorylation and p21 protein level in HN30 cells after treatment with 4 Gy, 
when compared to 4 Gy alone. 
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3.3 Show HN31’s partially functional p53 status will allow for sensitivity to persistent 
exposure to direct ROS, stimulating activation of the p53-p21 pathway, leading to an 
increase in senescence  
3.3.1.  Brief exposure to a high dose of H2O2 causes short term elevation of p21 
and ROS in mutp53 cells leading to a slight increase in senescence   
Noting that the difference in the baseline level of ROS between HN30 and HN31 was 
quite large, with HN31 being 2 to 3 fold higher than HN30 (Figure 18 and 19), we decided to 
investigate the possibility that cells with mutp53 may need a higher exposure to ROS, higher 
than the level produced using 4 Gy, in order to achieve a senescent state. DCFDA staining 
showed that treatment with 250µM of the ROS, hydrogen peroxide (H2O2), for one hour 
elevated the overall level of ROS to an 8 fold increase at the 24 hour time point in HN31 
cells, compared to just a 23% increase 24 hours after 4 Gy (Figure 25 and 19).  Yet, this 
increase was still significantly lower when compared to the 21 fold increase at 24 hours seen 
in HN30 cells under the same treatment. By 96 hours, while both cell lines were able to 
eliminate a majority of the intracellular ROS, the level of ROS seen in HN30 cells with H2O2 
treatment was almost equivalent to the level seen with exposure to 4 Gy, the level that is 
necessary to induce senescence.  However, HN31 cells were able to compensate for their 
massive ROS burst by reducing the ROS back down to their baseline level. Collectively, 
these results provide evidence that HNSCC cells, regardless of their p53 status, do still 
maintain redox capabilities; yet, cells with a mutation of TP53 seem to have acquired the 
ability to reduce ROS to a level that will diminish the amount of permanent cell damage.   
Still, with such a substantial increase of ROS after H2O2 treatment at the 24 hour time 
point in HN31 cells, we sought to determine if this initial burst would allow for any 
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alterations to the cell. In Figure 26, treatment with 250µM of H2O2 for one hour led to short-
term expression of the p21 protein in HN31 cells. SA-β-gal staining showed that this did 
indeed translate to a notable increase in senescence for the HN31 cell line (Figure 27 and 28).  
 To further examine the effect that this level of H2O2 treatment would have on p53 
activity, we looked at phospho-p53 and p21 protein levels over a 96 hour time course in 
HN31 cells. We found that H2O2 treatment led to a p53 dependent increase in p21 protein 
levels for extended time points (which did return back to baseline levels at 96 hours) when 
compared to the lack of increased p21 in irradiated cells (Figure 29).  These data support the 
concept that it is the level of ROS produced from exogenous sources that leads to increases in 
p21 levels, seemingly through p53, with an increase in senescence in these otherwise 
resistant HNSCC cells.  
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Figure 25. DCFDA staining showing the massive induction of ROS at 24 hours in 
both HN30 and HN31 cells treated with 250µM H2O2 when compared to 4 Gy, but only 
HN30 maintains the ROS at an elevated level. Error bars represent standard deviation of each 
sample performed in triplicate. 
 
 
 
 
 
 
 
Figure 26. Western blot of HNSCC cells treated with 250µM of H2O2 shows that 
high ROS exposure leads to an elevation of p21 in HN31 cells at 24 hours, but as ROS are 
depleted, the p21 level returns back to baseline at 96 hours. 
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Figure 27. SA-β-gal staining showing a slight increase in senescence in HN31 cells 
after treatment with 250µM of H2O2.  
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Figure 28. Quantitation of SA-β-gal positive senescent cells (those staining blue) 
from three independent experiments from four randomly selected fields in each well of cell 
lines shown in Figure 27. 
 
 
 
 
 
 
 
 
Figure 29.  Western blot showing a time course of the difference in p21 protein level 
and phosphorylation of p53 in HN31 cells after treatment with either 250µM of H2O2 or 4 
Gy. 
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3.3.2. HN31 cells have a partially functional A161S missense mutation and a 
non-functional C176F missense mutation 
As stated earlier, the HN31 cell line consists of two missense mutations on separate 
alleles, located at residues A161S and C176F. Ongoing research in our lab to establish a 
reliable classification system to apply TP53 as a prognostic biomarker for patient outcome 
was used to help evaluate the impact of these TP53 missense mutations.  The Evolutionary 
Action (EAp53) scoring system is a combination of two components: the Evolutionary Trace 
(ET) approach, in which functional sites can be predicted by identifying residues with large 
ET grades, a grade given to every sequence position to identify functional sensitivity to 
sequence variations, that will structurally cluster and overlap into evolutionary ‘hot spots’ 
(55), and observing when the amino acid change is least conservative. The EAp53 score for 
A161S classified this mutation as partially functional, and C176F as non-functional. This 
information allowed us insight in to how HN31 may be senescing when exposed to either 
overexpression of p21 or a burst of ROS, while its TP53 knockdown counterpart, HN31 
shp53 remained resistant.  
For the TP53 classification project, HNSCC TP53 null cell line, PCI-13, was used to 
create a variety of isogenic cell lines which differed only in a single TP53 mutation (Figure 
30). PCI-13 wild-type, pBABE (TP53 null), A161S, and C176F were among the cell lines 
created and were used for evaluation of the possible differences in functionality regarding 
radiation and exposure to various concentrations of ROS.  
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Figure 30. A detailed schematic of the process of inserting the TP53 wild-type gene 
into the HNSCC TP53 null cell line, PCI-13, then using site-directed mutagenesis to insert 
the A161S or the C176F mutations, and finally selecting with puromycin.  
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3.3.3.  PCI-13 cells exhibiting a null TP53, partially functional or non-functional 
TP53 status are resistant to radiation-induced senescence when compared to PCI-13 
cells expressing wild-type TP53  
To evaluate the radiosensitivity of the partially functional A161S mutation 
independent of the nonfunctional C176F mutation in comparison to wild-type TP53, a 
clonogenic assay was used and showed that the 4 Gy surviving fraction in TP53 null or 
mutant cells was significantly higher than in cells with wtp53 (Figure 31). SA-β-gal staining 
showed that 4 days after treatment with 4 Gy ionizing radiation, cells with wtp53 had a 
significantly higher SA-β-gal positive staining (48%) compared to the SA-β-gal positive 
staining in TP53 null and all TP53 mutant cells (less than 5%) (Figures 32 and 33).  These 
results indicate that HNSCC cells expressing mutant forms of TP53, even those classified as 
partially functional, or are null for TP53 are relatively radioresistant when compared to 
isogenic cells expressing wtp53, and that this radioresistance was still attributed to a lack of 
radiation-induced senescence. 
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Figure 31. Null and mutant TP53 PCI-13 cells are resistant to radiation when 
compared to PCI-13 cells expressing wild-type TP53. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Null and mutant TP53 PCI-13 cells are resistant to radiation-induced 
senescence when compared to PCI-13 cells expressing wild-type TP53 
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Figure 33. Quantitation of SA-β-gal positive senescent cells (those staining blue) 
from three independent experiments from four randomly selected fields in each well of cell 
lines show in Figure 32. 
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3.3.4.  Partially functional A161S mutation has induction of p21 24 hours after 4 
Gy, but still exhibits resistance to radiation-induced senescence 
To confirm if a similar mechanism of p21 induced senescence was occurring in the 
PCI-13 wtp53 cell line, as seen in HN30, we performed another set of experiments 
investigating p21’s mRNA and protein level after radiation treatment.  We measured the 
expression of the p21 gene by qRT-PCR at various times after exposure to 4 Gy ionizing 
radiation and among the mutp53 bearing cells, only PCI-13 A161S had minimal and short-
lived expression of the p21 gene compared to the enhanced long-term expression seen in 
PCI-13 wtp53. PCI-13 Neither PCI-13 C176F nor pBABE, TP53 null, cell lines had any 
elevation in p21 mRNA (Figure 34).  Western blot analysis demonstrated that long-term 
expression of the p21 protein can be seen in wtp53 cells, with no expression in PCI-13 
C176F or pBABE, and short term expression at the early time point of 24 hours in the PCI-13 
A161S cell line (Figure 35).   
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Figure 34. quantitative RT-PCR analysis of p21 mRNA expression showing p21 
mRNA level is significantly elevated at both 24 and 96 hours after 4 Gy in PCI-13 wt cells, 
slightly elevated only at 24 hours in A161S, with no increase in pBABE or C176F cells. 
Error bars represent standard deviation of each sample performed in duplicate.  
 
 
 
 
 
 
 
Figure 35. Western blot showing p21 protein is elevated at both 24 and 96 hours after 
4 Gy radiation in PCI-13 wt cells, slightly elevated only at 24 hours in A161S, with no 
increase in pBABE or C176F cells. 
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3.3.5.  The use of antioxidants causes a significant decrease in senescence in PCI-
13 wild-type TP53 cells. 
To confirm that the senescence seen in PCI-13 wt cells was indeed due to the impact 
of ROS on the p53-p21 pathway, PCI-13 wtp53 cells were treated with the antioxidant, n-
acetyl cysteine (NAC), two hours before exposure to 4 Gy and every 24 hours after, up to the 
96 hour time point at which the SA-β-gal staining was performed. This treatment, as in HN30 
cells, caused a significant decrease in the percentage of senescent cells after radiation 
exposure compared to wtp53 cells not receiving NAC (Figures 36 and 37). The use of 
DCFDA, confirms that daily treatment with NAC for 96 hours inhibited ROS production 
after radiation (Figure 38). 
 
 
 
 
 
 
 
Figure 36. SA-β-gal staining shows that the radiation induced senescence seen 4 days 
after 4 Gy in PCI-13 wild-type TP53 cells can be prevented with use of the antioxidant N-
acetyl cysteine (NAC). 
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Figure 37. Quantitation of senescent cells (those staining blue) in four randomly 
selected fields of the cell lines shown in Figure 36. 
 
 
 
 
 
 
 
 
 
Figure 38. DCFDA staining showing that the use of NAC everyday does inhibit the 
accumulation of ROS at the 96 hour time point, the time at which the SA-β-gal staining is 
performed. 
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3.3.6.  Brief exposure to a high dose of H2O2 causes long-term expression of p21 
and elevates senescence in PCI-13 wild-type p53 and PCI-13 A161S cells 
 As shown in Figure 26, the use of 250µM of H2O2 was able to elevate the level of 
p21 in HN31 cells at the 24 hour time point. We wanted to investigate the possibility that this 
increase may be due to the partial functionality of the A161S mutation.  In Figure 39, 
treatment with 250µM of H2O2 for one hour led to a long-term expression of p21 in not only 
PCI-13 wt cells but in the PCI-13 A161S cell line as well, albeit at a lower level. SA-β-gal 
staining showed that this did indeed translate to a significant increase in senescence for cells 
expressing the PCI-13 A161S mutation (Figures 40 and 41). These data support the concept 
that it is the level of ROS produced from exogenous sources that leads to induction of a 
partially functional TP53, triggering an elevation in p21 protein level, creating an increase in 
senescence in these otherwise resistant HNSCC cells.  
 
 
 
 
 
 
Figure 39. Western blot of HNSCC cells treated with 250µM of H2O2 shows that 
with high ROS exposure the level of p21 is elevated in both PCI-13 wt and A161S cells at 24 
hours and 96 hours, albeit at a lower level in A161S. 
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Figure 40. SA-β-gal staining showing a substantial increase in senescence in PCI-13 
A161S cells after treatment with 250µM of H2O2  
 
 
Figure 41. Quantitation of SA-β-gal positive senescent cells (those staining blue) 
from three independent experiments from four randomly selected fields in each well of cell 
lines shown in Figure 40.	   
0 
10 
20 
30 
40 
50 
60 
70 
80 
wt pBABE A161S C176F 
%
 se
ne
sc
en
t c
el
ls
 
no tx 
H2O2 
250 µM H2O2 - 
pBABE 
wt 
A161S 
C176F 
(250µM) 
76	  
	  
3.3.7.  Persistent exposure to a low dose of H2O2 results in ROS accumulation 
leading to long-term p53 phosphorylation, p21 transcription, and an increase in 
senescence in wild-type TP53 and partially functional TP53 HNSCC cells  
 To further investigate the hypothesis that mutp53 cells were better adapted to reduce 
the burst of ROS produced by 4 Gy or 250µM H2O2, which may contribute to their relative 
radioresistance, we attempted to sensitize these cells by generating an environment of 
constant exposure to low doses of ROS by exposing both wt, partially functional, non-
functional and null TP53 cells to 2 Gy or 50µM H2O2 every 24 hours for 96 hours. The 
protein level of both p21 and phosphorylated p53 remained elevated up to the 96 hour time 
point in HN30, HN31, PCI-13 wt and partially functional TP53 PCI-13 A161S cells when 
treated with 50µM H2O2 (Figure 42). However, when these same cell lines were treated with 
2 Gy every day, there was only measurable long-term protein expression of p21 in the wtp53 
and PCI-13 A161S cell lines (Figure 43). It was also noteworthy that the cell lines treated 
with NAC showed a lack of p21 and p-p53 protein expression, again, confirming the 
significant impact of ROS and its role in the p53-p21-senescence pathway.  
In HN31 cells, 50µM H2O2 treatment every day created a sustained 2 fold increase of 
ROS at the 96 hour time point, while the level of ROS after treatment with 2 Gy every day 
was only elevated 29%, almost identical to one dose of 4 Gy at the same time point (Figure 
44).  Also, the lack of ROS accumulation, using these same treatment conditions, in our 
HN30 shp21 cell line, confirmed p21’s role in regulating ROS (Figure 45). Long-term 
activation of p53, p21, ROS expression and its contribution to senescence is shown in 
Figures 46 and 47, in which there was a 35% increase in SA-β-gal staining in HN31 cells 
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treated with 50µM H2O2 every day compared to all other treatment types, which did not 
produce long-term elevated ROS or p21 expression. 
 
 
 
	  
Figure 42. Western blot showing that treatment with 50µM H2O2 for 1 hour everyday 
will allow for long-term expression of p21 and phosphorylated p53 in HN30, HN31, PCI-13 
wt, and PCI-13 A161S cells and that daily NAC treatment prevents these elevated levels. 	  
	  
	  
	  
	  
Figure 43. Western blot showing that treatment with 2 Gy everyday will allow for 
long-term expression of p21 and phosphorylated p53 in HN30, PCI-13 wt and PCI-13 A161S 
cells, but not HN31, and that daily NAC treatment prevents these elevated levels. 	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Figure 44. DCFDA staining performed 96 hours after indicated treatments shows 
HN31 cells exhibiting a long-term elevation of ROS when exposed to 50uM H2O2 everyday 
as compared to ROS levels that return to baseline in other treatments. Error bars represent 
standard deviation of each sample performed in triplicate.   
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Figure 45. DHE staining performed at 96 hours shows HN30 shp21 cells do not 
exhibit a long-term elevation of ROS when exposed to any indicated treatments, 
demonstrating the significant role p21 plays in regulating ROS. Error bars represent standard 
deviation of each sample performed in triplicate. 
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Figure 46. SA-β-gal staining showing a substantial increase in senescence in HN31 
cells after daily treatment with 50µM of H2O2, which was inhibited with the daily treatment 
of NAC. 
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Figure 47. Quantitation of SA-β-gal positive senescent cells (those staining blue) 
from three independent experiments from four randomly selected fields in each well of cell 
lines shown in Figure 46. 
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3.4  Demonstrate that direct transcription of p21 or elevation of ROS, by suppression of 
antioxidant levels, can be therapeutic approaches to sensitize radioresistant, partially 
functional p53 cells  
3.4.1.  Investigations into the possible mechanisms by which mutp53 HN31 cells 
are able to maintain and survive in a high ROS environment when compared to wtp53 
HN30 cells 
An mRNA array done by our lab showed an increase of the nucleotide excision repair 
gene, DDB2 after cisplatin treatment in TP53 wild-type HNSCC cells.  DDB2 has been 
attributed to repression of ROS scavenger genes upon oxidative stress and that mouse and 
human cells deficient in DDB2 do not undergo premature senescence, even when treated 
with H2O2 (209). And, being that DDB2 is a p53 regulated gene (210), we were interested to 
see if all of these characteristics could play a role in HN31’s radioresistance. Figure 48 
showed that there was a clear difference in the baseline level of DDB2 between the wtp53 
HN30 cell line and the mutp53 HN31 cell line. It could be inferred that higher baseline ROS 
levels in HN31 cells are sustainable due to an elevation of antioxidant genes, attributed to the 
lower baseline level of DDB2 protein.  We also see that DDB2 is functional in HN30 cells 
due to its increased level when exposed to radiation. 
 An ongoing project within our lab has focused on malic enzyme (ME) regulation of 
ROS under the treatment of various chemotherapy agents. A recent publication by Jiang, et 
al. (147) stimulated interest in this field because it demonstrated a feedback loop allowing for 
the stabilization of p53 through downregulation of ME1 and ME2, via suppression of MDM2 
and ROS-induced AMPK activation, respectively; and that p53’s activation keeps ME1 and 
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ME2 levels inhibited through binding to their response elements. It was of interest to see if 
radiation would differently affect the ME1 or ME2 levels between wtp53 and mutp53 
HNSCC cells. Firstly, the lack of expression of ME2 in HN31, when compared to HN30, 
seen in Figure 49, was a clear indicator that HN31 was using the cells’ metabolism to keep 
ROS elevated at a baseline level.   Indeed, a time course after 4 Gy between HN30 and HN31 
cells showed that HN31 cells elevated ME2 to assist in suppression of the initial burst of 
ROS seen in Figure 18 and remained elevated to continue to avoid senescence induced by 
ROS.  While, on-the-other-hand, HN30 cells decreased the level of ME2 to allow for an 
elevation of ROS, phosphorylation of p53, transcription of p21, and therefore senescence 
(Figures 50, 19, 7, and 2). 
 Nrf2 is pivotal in activation of antioxidants in response to an elevation of ROS and 
depending on the level of oxidative stress,  p21 has been shown to compete with Keap-1 (the 
negative regulator for Nrf2) for binding, thus inhibiting its ubiquitination (182).  To 
investigate the possibility that p21 may be regulating ROS through Nrf2, we performed a 
western blot analysis of a variety of conditions known to elevate both p21 and ROS in HN30 
and HN31 cells, and, as a positive control, we used the MSK922 HNSCC cell line (which 
overexpresses Nrf2 due to two genetic mutations).  In Figure 50, at the 24 hour time point in 
HN30 cells, under all conditions, there was an elevation of Nrf2, yet at later time points, this 
level returns back to baseline, even while p21 remains elevated. This data showed us that 
elevation of Nrf2 was an immediate response of the cell to an elevation of ROS, yet as the 
cells continue to endure the prolonged oxidative stress caused by radiation, Nrf2 levels were 
reduced such that the cell could enter the senescent state. Overall, our data demonstrates that 
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Nrf2 degradation is not inhibited by p21 if the state of the cells is such that DNA repair 
cannot be facilitated. 
Figure 50 also gave evidence of the overexpression of Nrf2 at baseline in MSK922 
and HN31 when compared to HN30. To investigate if the overexpression of this antioxidant 
affected the baseline ROS level in MSK922, hypothesizing that it would be elevated as seen 
in HN31 in Figures 18 and 19, a DCFDA assay was performed. Indeed, MSK922 cells had a 
significantly higher ROS level than HN30 cells, and comparable to HN31 cells (Figure 51). 
This data was another contribution to the point that HN31 cells were able to survive in a high 
ROS environment due to maintenance of elevated antioxidant levels.   
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Figure 48.  Western blot showing DDB2 protein is slightly elevated in HN30 cells 
when exposed to radiation, regardless of NAC treatment, and that HN31 cells have a lower 
baseline level of DDB2, when compared to HN30, which remains unchanged under all 
treatment conditions.  
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Western blot showing ME2 levels decrease at later time points in HN30 
cells after treatment with 4 Gy, while there is an increase of ME2 in HN31 cells. ME1 is not 
effected by radiation, nor is there a difference between cell lines. 
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 Figure 50. Western blot showing Nrf2 protein level after various treatments known to 
induce ROS and p21 in HN30 and HN31 cells. Positive control MSK922 cells have two 
mutations on the NFE2L2 (Nrf2) gene causing its overexpression. 
 
 
Figure 51. DCFDA analysis showing that baseline ROS levels of HN31 and 
MSK922, both having a higher native level of Nrf2, are significantly higher compared to 
HN30, which exhibit a lower native level of the Nrf2 protein. Error bars represent standard 
deviation of each sample performed in triplicate.   
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3.4.2.  Therapeutic approaches to sensitize radioresistant HN31 cells via direct 
transcription of p21 or elevation of ROS by suppression of antioxidant levels 
 Sodium Butyrate (NaB) is a histone deacetylase inhibitor (HDACi), well established 
in transcribing p21 through histone hyperacetylation and has been proposed for potential use 
as cancer treatment (76).  After seeing the significant effect overexpression of transient p21 
had on inducing senescence in HN31 cells (Figures 16 and 17), we were interested to see if 
we could achieve a similar effect using NaB’s ability to elevate p21. As seen in Figure 52, 
NaB was able to increase the protein level of p21, and its level was decreased over a 
timecourse spanning 96 hours. Figure 53 showed that at 96 hours, in HN30 cells, NaB 
treatment alone (cells were treated twice, at 0 and 48 hours in order to keep p21 elevated) 
was not sufficient to keep p21 elevated, but in combination with 2 Gy (given at 24 hours) the 
level of p21 stayed sustained at a higher level than 2 Gy alone. In HN31 cells, only with 
treatment of NaB twice in combination with 2 Gy were we able to see long term elevation of 
p21. To examine if NaB alone was able to elevate ROS and if the combination treatment had 
a greater effect on ROS than any treatment alone, a DCFDA staining was performed. Figure 
54 showed us that, indeed, NaB elevated ROS at the 24 time point, but as the chemical lost 
its effect on transcription of p21, the ROS decreased in both HN30 and HN31. Further 
analysis showed that the combination treatment significantly elevated ROS levels in HN30 
and HN31 cells.  Figure 55 concluded that HN31 cells can be radiosensitized and become 
significantly senescent when NaB treatment is used to elevate p21. 
 β-phenethyl isothiocyanate (PEITC) is a natural compound known to cause ROS 
accumulation by binding with and inhibiting the antioxidant, glutathione.  Preliminary data 
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performed by our collaborators in Thailand showed that with the use of MTT and clonogenic 
assays, 7µM of PEITC can preferentially inhibit the growth of HNSCC cell lines SCC15, 
SCC9, SCC4, SCC25, FaDu, Cal-27, and TU138 (data not shown). Figure 56 demonstrated 
that in the HNSCC cell line Tu138, treatment with the IC50 of PEITC, 7µM, for either 24 or 
48 hours did significantly increase ROS levels.  This, along with other data, allowed for the 
development of a flank mouse model using Tu138, partially functional p53 cells and daily 
treatment of 5mg/kg of PEITC. Figure 57 showed that treatment of 5mg/kg of PEITC did 
significantly decrease tumor size when compared to the non-treated group and Figure 58 
showed a significantly lower tumor area at the time of death when compared to the non-
treated group. Further work into the mechanism of how this drug is able to inhibit the 
proliferation and growth of these tumors is currently being pursued. 
	  
	  
	  
	  
	  
Figure 52. Western blot of HN30 and HN31 cells showing p21 levels during a 
timecourse after treatment with 2mM NaB.  
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Figure 53. Western blot at the 96 hour time point shows that p21 protein level can be 
elevated, regardless of p53 status, using a combination therapy of two treatments with 2mM 
of NaB, at 0 hours and 48 hours, with 2 Gy, at 24 hours.  
 
 
 
 
Figure 54. DCFDA staining shows that multiple treatments with NaB in combination 
with a single dose of 2 Gy, keeps ROS levels significantly elevated in both cell HN30 and 
HN31 cell lines. Error bars represent standard deviation of each sample performed in 
triplicate. 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
HN30 HN31 
fo
ld
 c
ha
ng
e 
 (D
C
FD
A
) NT 
NaB 1x 24hr 
NaB 2x 96hr 
2Gy at 24hr 
2Gy at 72hr 
NaB 1x and 2Gy at 96hr 
NaB 2x and 2Gy at 96hr 
90	  
	  
 
 
 
           
 
 
Figure 55. Since the combination treatment of NaB with radiation allows for long-
term elevation of p21 and ROS, quantitation of senescent cells (those staining blue) in four 
randomly selected fields shows that there is a significant increase in senescence not only in 
HN30 cells but in HN31 cells, having the partially functional TP53 mutation, A161S. 
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Figure 56. DCFDA analysis shows that the use of 7µM of PEITC for 24 or 48 hours 
significantly increases ROS in Tu138 cells. Error bars represent standard deviation of each 
sample performed in duplicate.	  
	  
	  	  	  	  	  	   	  
 
Figure 57. 5 mg/kg PEITC treatment group has significantly lower tumor volume 
than the control. Bonferini post test: * = p<0.05, ** = p<0.01, *** = p<0.001 
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Figure 58.  Histologic measurement of tumor area at time of death in TU138 
xenograft shows that the 5 mg/kg PEITC group has significantly lower tumor area than the 
control. One-way ANOVA: * = p<0.0121  
 
 
 
 
 
 
 
 
 
 
 
 
PEITC 
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Chapter 4: Conclusions, Discussion, Significance 
 Conclusions 
! HNSCC cells harboring a mutation of TP53 (mutp53) are resistant to radiation 
induced senescence and have elevated reactive oxygen species (ROS) under normal 
cell culture conditions compared to HNSCC cells with wild-type TP53 (wtp53). 
! The level of ROS produced by multiple doses of ionizing radiation are quickly 
eliminated in mutp53 cells, most likely contributing to their radioresistance but, 
persistent exposure to direct ROS, via H2O2, creates a long-term,  stress induced 
environment in which cells with a partially functional p53 will finally senesce at a 
significant level.  
! The loss of p53’s ability to transcribe p21 in mutp53 cells is a crucial component in 
creating their radioresistance, due to p21’s ability in regulating ROS. 
! The level and duration of elevated ROS, regulated by long term expression of p21, in 
cells with wild-type or partially functional p53 are the key factors in causing 
premature senescence in HNSCC. 
! HNSCC cells with partially functional p53 status are resistant to radiation induced 
senescence, but can be sensitized by the following methods: 
! Elevation of p21, in combination with radiation 
! Maintenance of cells in an elevated ROS environment 
! Sodium butyrate treatment, a chemical that induces p21 transcription, in 
combination with radiation  
! PEITC treatment, an antioxidant suppressing drug, in a flank mouse model 
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Discussion 
Given the prominent role of radiation therapy in the treatment of HNSCC, 
understanding the mechanisms of radiation resistance is of the utmost importance.  Here, we 
showed that wtp53 HNSCC cells become terminally senescent after exposure to ionizing 
radiation, whereas mutp53 HNSCC were relatively radioresistant and avoid cell death.  We 
also established that the ability of HNSCC to senesce was due to the long-term expression of 
p21 whose transcription, under these conditions, was dependent on the functional status of 
TP53, and whose stability led to elevation and prolonged expression of ROS.  We also 
determined that HNSCC cells with a mutant TP53 were relatively radioresistant because the 
level and duration of ROS produced from multiple doses of 2Gy was not high enough to 
achieve a threshold necessary for cell senescence.  But, with prolonged exposure to low 
doses of H2O2, an accumulation of this level of ROS led to senescence in cells with a 
partially functional TP53, by the same mechanism as seen in wtp53 cells.  
After confirming that p16 was silenced in these HNSCC cells and could not 
participate in inducing senescence, it was important to establish the role of the p53/p21 
pathway. Since p53 has been shown to be a transcription factor for genes other than p21 that 
can regulate senescence	   (211), we needed to confirm that the senescent phenotype was 
primarily dependent on p21.  We used shRNA knockdown of p21 in cells with wtp53 and 
after treatment with radiation, these cells showed significant resistance to senescence. These 
results demonstrated that senescence in HNSCC cells is mediated primarily through p21, as 
opposed to other downstream p53 targets.   
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p21’s influence on oxidative balance and the cell’s response to modulation in the 
levels of p21 or ROS is varied, dependent on cell type, level and duration of p21 expression 
and the amount of ROS produced.  How exactly p21 is able to regulate ROS is a burgeoning 
field of interest, yet remains to be completely understood. p21 is not a transcription factor, 
yet the indirect effects of its functions have been shown to influence cellular gene expression.  
For example, p21’s inhibition of CDK results in dephosphorylation of Rb, therefore 
inhibiting E2F transcription factors (68). Also, it has been shown that p21’s inhibition of 
cdk2-cyclinE activity stimulated NF-κB dependent transcription through its interaction with 
transcriptional cofactor p300 (212). This is significant due to the well-established role of NF-
κB in targeting genes directly effecting ROS, such as MnSOD, glutathione peroxidase-1 and 
NADPH oxidase NOX2, just to name a few (213).  
Chang, et al. showed that p21-induction leads to an increased expression of a number 
of genes associated with extra cellular matrix proteins, lysosomal enzymes, and 
mitochondrial proteins (214).  Being that mitochondria are a significant source of ROS 
within the cell (215), Masgras, et al. developed a p21 inducible system to show that increases 
in p21 lead to strong mitochondrial membrane hyperpolarization and increased mitochondrial 
mass (216), both of which are associated with cells undergoing senescence (217,218). 
Finally, pro-oxidant gene, PIG3, indicated to be important for elevation of ROS after p53 
expression	   (57), was shown to increase at both the mRNA and protein level after the p53 
independent direct elevation of p21. 
We continued our work into understanding how mutp53 cells were able to sustain 
themselves in a high ROS environment, which, as a byproduct, gave them the necessary 
adaptations to become radioresistant. We consistently observed that HN31 had a 2 to 3 fold 
100	  
	  
higher basal level of ROS relative to its isogenic partner, HN30. The high basal levels of 
ROS in HN31 suggested that their radioresistance may be due to an adaption of these cells to 
a higher ROS environment, as others have shown that altered cellular antioxidant levels or 
mitochondrial production of ROS can influence the sensitivity of mutp53 cells to radiation 
(216,219,220).  
Our data concluded that mutp53 cells seem to be able to keep antioxidant levels 
elevated along with elevated ROS. We discovered HN31, when compared to HN30 cells in 
their natural state, had an elevated level of the antioxidant protein, Nrf-2, and were able to 
suppress proteins affiliated with inhibiting antioxidants, DDB2, or proteins affiliated with 
metabolic repression of ROS, ME2. In a well summarized review by Trachootham, et al 
(221), approaches to overcoming chemo and radioresistance in cancer treatment are currently 
being pursued by use of ROS modulating agents in a number of different cancer types. 
Although increasing p21 transcription in combination with radiation causes HNSCC 
cells to senesce, some studies suggest that elevated p21 levels may have oncogenic effects 
(74).  For example, Campisi recognized in normal senescent cells, there was an 
overproduction of various mitogenic factors and an ability of the cell to avoid apoptosis 
(222).  Chang, et al. took this information one step further and created a p21 inducible system 
in a firbrosarcoma cell line and showed that p21 induction itself could result in similar 
changes in gene expression (214).  Since these experiments were done in either normal cells 
or soft tissue carcinoma cells, it is very possible that these effects of p21 are cell type 
specific. Although we did not address these issues with this study,  the knockdown of p21 in 
our HN30 cell line would provide us with the appropriate resource to further investigate the 
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possibility that p21 might be able to stimulate proliferation of neighboring cells, albeit 
unlikely. 
Having established that elevation of p21, in combination with radiation, and that 
long-term persistent exposure to ROS both were able to cause senescence in partially 
functional, radioresistant mutp53 cells, we developed strategies to effectively apply this data 
to the realm of chemo/radiotherapy.  HDAC inhibitors are a class of anti-tumor agents able to 
inhibit tumor growth in vivo via their ability to deacetylate histones, therefore affecting gene 
expression (223-225). NaB, is a member of this class of drugs and was chosen due to its 
specificity for HDAC family 1 and 2 and for its known ability to elevate p21.  In order to 
keep p21 levels elevated, NaB was added to the media at the beginning and middle of the 96 
hour experiment; this, in combination with radiation 24 hours after NaB addition, to elevate 
the ROS above a threshold in which partially functional TP53 cells would not be able to 
withstand, was able to keep ROS elevated, long term, and significantly increase senescence 
in HN31 cells.  
β-phenethyl isothiocyanate (PEITC) is known to cause ROS accumulation by 
inhibiting the antioxidant glutathione and has been shown to preferentially kill ovarian cancer 
and primary leukemia cells (198,226,227).  Having established that the baseline level of 
HN31 is 2 to 3 fold higher than that seen in HN30 and with the preliminary data showing that 
this had become a sustainable environment for HN31 cells due to their ability to regulate 
proteins affiliated with antioxidant balance, it seemed very likely that treatment with this 
drug would have sensitizing effects on HN31 cells. Unfortunately, the mouse experiment 
involving PEITC treatment was done prior to acquiring the results associated with HN31, but 
the data produced from the mouse work is significant, none-the-less. PEITC elevated ROS in 
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the HNSSC cell line, Tu138, inhibited cell proliferation in vitro, and with daily treatment in 
an orthotopic mouse model, inhibited tumor growth.  
Overall, this data is very encouraging and offer a rationale to consider the use of 
either ROS inducing agents or therapies that increase p21 expression in combination with 
radiation as approaches in HNSCC cancer therapy.   
DDB2 is encoded by the nucleotide excision repair (NER) XPE gene (228) and has 
been shown to be involved in the early DNA damage steps of NER (229).  Exposure to either 
radiation or UV has been shown to activate the transcription of DDB2, only in wild-type p53 
cells, not in p53 null cells (230).  Also, both DDB2 deficient MEF cells and HCT116 cells 
expressing DDB2 shRNA were found to have high expression of the antioxidants, catalase 
and MnSOD. When DDB2 was re-expressed in these cells, the antioxidant genes were 
suppressed (209). Our data shows that HN30 cells slightly elevated DDB2 after exposure to 
radiation even in the presence of NAC. Figure 24 showed that even with daily treatment of 
NAC there was still enough cell stress caused by radiation, independent of ROS, which 
allowed for some phosphorylation and therefore transcriptional activation of p53. Being that 
DDB2 is associated with early DNA repair steps, it seemed odd that it would remain elevated 
out to the 96 hour time point in the HN30 cell line. Unfortunately, it is difficult to distinguish 
if this slight elevation may be the level at which the cells are either attempting repair or, 
attempted to senesce by implementing suppression of antioxidants. A positive control in 
which the cell stress is such that the HN30 cells could recover, i.e. a lower dose of radiation 
or a very low dose of H2O2, or possibly an earlier time point of this same treatment, being 
that NER is an early DNA damage repair mechanism, may be necessary to help answer these 
questions. Finally, it is also interesting to note that, in HN31 cells, the low baseline of DDB2 
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and its non-responsiveness to radiation are strong evidence toward the hypothesis that these 
mutp53 cells have acquired the ability to regulate genes responsible for antioxidant 
expression.  
Malic enzymes, ME1 and ME2, have recently become novel targets in the field of 
p53’s regulation of metabolism. ME1 is the cytosolic NADP+- dependent isoform, while 
ME2 is the mitochondrial NADP+ - dependent isoform. A recent article (147), intricately 
showed that p53 down-regulation of ME1 reduces MDM2 expression allowing for p53 
activation and that down-regulation of ME2 elevates ROS, activating p53 and AMPK leading 
to induction of senescence. And, in turn, the down-regulation of these enzymes was shown to 
increase the phosphorylation of p53 and p21 causing senescence. 
Our work shows that ME1, at a baseline level, is similar between HN30 and HN31 
cells and is sustained throughout a time course post radiation treatment, meaning that 
cytosolic regulation of NADPH production is not affected by changes in ROS or p53 in these 
cell lines. Interestingly, not only is there a striking difference in the baseline level of ME2 
between HN30 and HN31, but there is a very definitive change in its expression over a time 
course after exposure to radiation. ME2 levels are significantly lower in HN31 cells at 
baseline when compared to HN30 cells. This is a clear indicator that HN31 cells have altered 
their metabolism, supposedly through its mutation of TP53, to keep ME2 suppressed in order 
to keep ROS elevated. When HN31 cells are exposed to radiation, they do have an initial 
burst of ROS (Figure 18), which must be regulated so that the cells can avoid cell death. 
Appropriately, ME2 levels elevate in order to suppress these ROS long term. HN30 cells 
respond in the opposite manner. Sensing that the DNA damage and ROS elevation caused by 
radiation in these cells is so great, cell death, not cell repair must be initiated, HN30 cells, by 
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decreasing their ME2 levels, allow for a greater increase of ROS, keeping p53 
phosphorylated, p21 elevated, leading to induction of senescence. 
Figure 50 showed the elevation of the Nrf2 protein at the early time point of 24 hours 
after treatment with either 4 Gy, 2 Gy, H2O2, or NaB in HN30 cells, with its decrease back to 
baseline by 96 hours after treatment with 4 Gy. It may seem confusing that DCFDA staining 
showed elevation of ROS at 24 hours in HN30 cells while this western blot shows an 
elevation of the antioxidant, Nrf2. This response can be explained by understanding the 
mechanism in which p21 responds to oxidative stress. Firstly, the Nrf2-interacting motif is on 
the C-terminal 154KRR site (75) overlap a cyclin-binding motif (CY2) and the PCNA 
interacting domain, while the N-terminal contains a CDK2 specific binding site and another 
cyclin-binding motif (CY1). The N-terminal CY1 motif is established as having a greater 
capability for cell cycle inhibition than CY2 (231). So, it would seem that cell cycle arrest 
mediated by p21 and p21’s upregulation of Nrf2 may be two separate response mechanisms 
to elevated ROS.  The chosen pathway, between Nrf2 or cell cycle arrest, most likely 
depends on the type and level of oxidative stress introduced.  Nrf2 could be considered as a 
primary protective mechanism, such that the cell damage caused by the oxidative stress may 
seem repairable, but if the stress continues, or is initiated at a level above which the cell can 
repair the damage, either apoptosis or, in the case of HNSCC cells, senescence would occur 
(232).  
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Significance 
The significance of this work is that it contributes to understanding the mechanism by 
which head and neck squamous cell carcinoma (HNSCC) cells exhibit radioresistance and 
offers approaches on how to overcome it. As locoregional recurrence is the most frequent 
cause of death from HNSCC, and may be caused by resistant to radiation, the efficacy of 
radiotherapy in controlling this disease is critically important for patient survival. 
Unfortunately, even with the multitude of treatment options available for HNSCC patients, 
many still experience treatment failure leading to disease recurrence and metastasis.  
Both p21 and ROS have been shown to be involved in senescence, and although the 
complex relationship between p21 expression and ROS production has been studied for many 
years, questions as to how p21 and ROS regulate one another’s expression remain. We show 
here evidence of a signaling pathway where the level and duration of ROS introduced are the 
determining factors in the initiation of either wild-type or partially functional p53 to 
transcribe p21.  The long term, elevated expression of p21, in turn, sustains the level of 
elevated ROS, causing HNSCC cells to undergo cell death via a senescence mediated 
pathway. The present study also opens the possibility of two approaches to radiosensitizing 
mutp53 cells: therapies to upregulate p21, which control expression of ROS, or directly 
increasing ROS production above a threshold to which these cells are able to recover. 
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Chapter 5: Future Directions 
Our data definitively show that the HN31 cell line, derived from a patient’s cervical 
metastasis, has a higher baseline ROS level compared to its isogenic primary tumor, HN30. 
We attribute this elevated sustainable ROS environment to elevated antioxidant levels. We 
demonstrate that proteins affiliated with altering antioxidant levels can be manipulated by 
HN31 cells to gain the advantages of having elevated ROS levels (i.e. stimulation of cell 
differentiation and proliferation). Determining specific antioxidant genes that are elevated in 
HN31 would be helpful in directing the suppression of them using targeted therapies.  
There are methods available to specifically measure the activity of superoxide 
dismutase (SOD), catalase, or glutathione peroxidase (Gpx) (233). There are also agents 
available to target these specific antioxidant enzymes	   (221). This approach should be 
implemented in combination with radiation due to the fact that suppressing antioxidants 
would then make these cells susceptible to the elevated ROS created by radiation.  
We are able to establish that indeed p21 can specifically elevate ROS levels through 
the use of transient over expression of p21, causing the increase of the overall level of ROS, 
and with the knockdown of p21, allowing for a lack of long term superoxide elevation. The 
missing aspect of this work is: by what mechanism is p21 controlling ROS? This is a 
question that has been asked for decades with only a few validated targets having been 
defined. There is recent evidence that p21 is able to indirectly influence the transcription of 
genes associated with ROS production.  Perkins et al. showed a pathway involving p21’s 
inhibition of cdk2-cyclinE activity which stimulated NF-κB dependent transcription through 
its interaction with transcriptional cofactor p300 (212).  They initially associated p21 and 
107	  
	  
NF-κB by the very general fact that they were both linked to growth arrest and cellular 
differentiation and they both could be activated by serum factors, okadaic acid, and phorobol 
esters.   
Passos et al. established an elaborate pathway in which DNA damage triggers 
mitochondrial dysfunction, enhancing ROS through a linear signal transduction pathway of 
p53-p21-GADD45-MAPK14-GRB2-TGFB2-TGFβ, noting that p21 has a direct binding with 
GADD45 (234,235) and that both TGFβ and MAPK14 activation can elevate ROS 
production (236,237). This group used multiple databases involving functional integrated 
interaction networks, protein phosphorylation data, cluster analysis of candidate pathway 
genes, and stochastic simulations in order to establish this particular pathway. 
It seems that in order to answer the looming question of how p21 influences ROS, the 
initial approach can be very overwhelming. Chang, et al. used a well-designed approach 
which contributed novel data to this field (214). A cDNA array hybridization was performed 
after using an inducible promoter to overexpress p21 in fibrosarcoma cells and it the results 
showed expression changes for genes associated with senescence, mitochondrial and 
lysosomal genes, ECM components, chromosome assembly and DNA replication. The HN30 
Lenti and HN30 shp21 cell lines are a great resource to apply this type of experiment. After 
exposing the cell lines to 4 Gy, differences in gene expression between the HN30 Lenti and 
HN30 shp21 at 24 hours and 96 hours would be compared. The results would help determine 
how p21 could be influencing ROS in HNSCC. Once target genes have been established 
identifying a pathway would be narrowed down significantly.  
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